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Abstract 
Recombinant expression and activity of cationic antimicrobial peptides 
 
In the past 60 years, antibiotics have been critical in the fight against infectious disease caused by 
microorganisms. The increasing bacterial resistance to antibiotics is a serious public health 
problem. Much research has been dedicated to the development of new classes of antibiotics to 
overcome this situation.  
Antimicrobial peptides (AMPs) are generally defined as peptides of less than 50 amino acid 
residues, bearing positive charge due to multiple lysine and arginine residues and with 50% or 
more of hydrophobic residues. AMPs have aroused great interest due to their broad spectrum of 
antimicrobial activity against Gram-positive and Gram-negative bacteria, fungi, protozoa and some 
viruses and their ability to overcome bacterial resistance. 
The major problem for the chemical production of AMPs is the elevated cost. Recombinant 
expression techniques for large-scale production of these peptides would represent an 
economically more viable approach. Therefore, strategies to produce AMPs at affordable cost are 
much required for the exploitation of their therapeutic potential. This was one of the main 
objectives of this thesis: the recombinant production and purification of two AMPs (Magainin-2 and 
LL37) using a family 3 carbohydrate-binding module (CBM3) from Clostridium thermocellum as 
fusion partner. The use of the CBM3 could reduce the purification costs using cellulose as affinity 
matrix. The other purpose was to evaluate the biological activities of recombinant LL37 and its 
therapeutic effects in mice models of wound healing, after topical application. 
The general introduction of this thesis is presented in chapter 1 and includes a bibliographic 
revision of: 1) the antimicrobial peptides; 2) a brief revision of carbohydrate-binding modules and 
their potential as fusion partners; 3) The frog AMP magainin-2; 4) the human AMP LL37; and 5) 
the wound healing process.  
In chapter 2, the expression of the AMP magainin-2 (MAG2) is described. MAG2 was fused to the 
N- and C-termini of the CBM3 containing a linker sequence (LK-CBM3), and formic acid 
recognition site between the two modules, for chemical cleavage. The recombinant protein MAG2-
LK-CBM3 was expressed in Escherichia coli BL21 (DE3) and LK-CBM3-MAG2 in E. coli M15 
(pREP4). The N-terminal MAG2 from the first construction was successfully cleaved and purified 
from the fusion partner LK-CBM3. However, the peptide showed no antibacterial activity against E. 
coli K12. The negatively charged C-terminal aspartic acid left from the acid cleavage may be the 
cause for the absence of antimicrobial activity. The expression of C-terminal MAG2 from the 
second construct was not successful. The peptide may have suffered proteolysis during the 
recombinant expression. 
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Chapter 3 describes the expression of the human LL37. The protein was also cloned to the N- and 
C-termini of LK-CBM3 and a formic acid recognition site was introduced between the two modules, 
allowing the isolation of LL37 after chemical cleavage. The recombinant proteins were expressed 
in E. coli BL21 (DE3) and solubilized with Triton X-100. The purification was achieved using 
cellulose CF11 fibers, taking advantage of the CBM3 specific affinity for cellulose; after hydrolysis 
with formic acid, LL37 was further purified by reverse-phase HPLC. Only the recombinant LL37 
obtained from the C-terminally fused protein (LK-CBM3-LL37) showed antibacterial activity against 
E. coli K12, with a MIC of 180 !g/ml. 
The biological activity of the recombinant P-LL37 with a N-terminus proline resulting from the 
chemical cleavage was confirmed in chapter 4. Also, wound healing experiments were performed 
in dexamethasone-treated mice to study the effect of LL37 on angiogenesis and wound 
regeneration. P-LL37 neutralized the activation of macrophages by lipopolysaccharide (LPS) and 
induced proliferation, migration and tubule-like structures formation by endothelial cells. The 
topical application of synthetic or recombinant LL37 on mice wounds increased vascularization 
and re-epithelialization, accelerating the healing process. 
After the confirmation that P-LL37 preserves its biological activities and accelerated wound 
healing, we tested the adjuvant activity of CRAMP and P-LL37 using Candida albicans protease 
Sap2 as antigen. We also evaluated the wound healing effects of topically added LL37 on diabetic 
mice. These experiments are described in the chapter 5. The administration of CRAMP or P-LL37 
with Sap2 did not increase the production of Sap2-specific serum IgG antibody, i.e. no adjuvant 
activity was detected for both peptides. The topical application of LL37 on diabetic mice wounds 
did not accelerate the healing process very significantly. However, histological analysis after 13 
days showed encouraging results. In fact, they revealed that the wounds treated with LL37 were 
smaller and presented several new skin annexa that could originate new hair, which may translate 
a more effective tissue regeneration. 
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Resumo 
Expressão recombinante e atividade de péptidos antimicrobianos catiónicos 
 
Nos últimos 60 anos, os antibióticos têm sido cruciais no combate contra doenças infecciosas 
causadas por microrganismos. A resistência crescente destes microrganismos aos antibióticos 
tornou-se um sério problema de saúde pública. Para combater esta situação, muita investigação 
tem sido desenvolvida para produzir novos tipos de antibióticos. 
Os péptidos antimicrobianos (Antimicrobial Peptides - AMPs) são geralmente definidos como 
péptidos com menos de 50 aminoácidos, com carga positiva devido à presença de múltiplas 
lisinas e argininas e com mais de 50% de aminoácidos hidrofóbicos. Os AMPS têm gerado grande 
interesse pelo facto de apresentarem um largo espectro de atividade antimicrobiana contra 
bactérias Gram-positivas e Gram-negativas, fungos, protozoários e pela capacidade de 
ultrapassarem os mecanismos de resistência a antibióticos. 
A síntese química para a produção de AMPs apresenta custos elevados; alternativamente, as 
técnicas de expressão recombinante podem ser mais viáveis, economicamente, para uma 
produção em larga escala, permitindo assim a introdução desta nova geração de antibióticos na 
prática clínica. Este foi então um dos principais objectivos desta tese: a produção recombinante 
de dois péptidos antimicrobianos (Magainina-2 e LL37) usando como proteína de fusão um 
domínio de ligação a carbohidratos de família 3 (Carbohydrate-binding module - CBM3), 
proveniente de Clostridium thermocellum. A utilização deste CBM3 poderá reduzir os custos do 
processo de purificação usando celulose com matriz de afinidade. O outro objectivo consistiu na 
avaliação das propriedades biológicas do péptido recombinante LL37 e o seu potencial 
terapêutico na cicatrização de feridas após aplicação tópica.   
A introdução geral desta tese está apresentada no capítulo 1 e inclui uma revisão bibliográfica de: 
1) péptidos antimicrobianos; 2) uma breve revisão dos CBMs e do seu potencial como proteínas 
de fusão; 3) o AMP de rã magainina-2; 4) o AMP humano LL37; e 5) o processo de 
cicatrização/regeneração de feridas. 
O capítulo 2 descreve a clonagem do AMP magainina-2 (MAG2) nos lados N- e C-terminal do 
CBM3, incluindo o espaçador (LK-CBM3). Foi ainda introduzido na construção, entre os dois 
módulos, um local de reconhecimento para hidrólise química com ácido fórmico. A proteína 
recombinante MAG2-LK-CBM3 foi expressa em Escherichia coli BL21 (DE3) e a proteína LK-
CBM3-MAG2 em E. coli M15 (pREP4). A MAG2 no N-terminal da primeira construção foi 
expressa, clivada e purificada com sucesso. No entanto, o péptido não apresentou atividade 
antimicrobiana contra E. coli K12. A presença de um resíduo carregado negativamente  
(aspartato) no lado C-terminal da MAG2, poderá causar a ausência de atividade. Este resíduo não 
está presente no péptido nativo, resultando da introdução da sequência aspartato-prolina na 
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construção, para permitir a hidrólise ácida. A expressão da MAG2 no lado C-terminal do LK-CBM3 
não teve sucesso. O péptido poderá ter sofrido proteólise durante a expressão em E. coli. 
No capítulo 3 descreve-se a expressão do AMP humano LL37. Este foi também clonado nos 
lados N- e C-terminal do LK-CBM3. De igual modo, introduziu-se o local para hidrólise química 
com ácido fórmico entre os dois módulos, para permitir a separação da LL37. As duas proteínas 
recombinantes foram expressas em E. coli BL21 (DE3) e solubilizadas com Triton X-100. A 
purificação foi efectuada usando fibras de celulose CF11, beneficiando da afinidade específica do 
CBM3 para este material; após hidrólise com ácido fórmico, LL37 foi purificada por RP-HPLC. A 
LL37 proveniente do C-terminal da proteína de fusão (LK-CBM3-LL37) foi a única a apresentar 
atividade antimicrobiana contra E. coli K12, com uma MIC de 180 !g/ml. 
As atividades biológicas do péptido recombinante P-LL37, com uma prolina no lado N-terminal 
resultante da hidrólise química, foram confirmadas no capítulo 4. Além disso, o efeito da LL37 na 
angiogénese e cicatrização de feridas foi avaliada em ratinhos tratados com dexametasona. P-
LL37 neutralizou a ativação de macrófagos por lipopolissacáridos e induziu a proliferação, 
migração e formação de vasos em células endoteliais.  A aplicação tópica de LL37 sintética ou 
recombinante nas feridas de ratinhos aumentou a vascularização e re-epitelialização, acelerando 
o processo de cicatrização. 
Após ter sido confirmado que o péptido recombinante P-LL37 conserva as suas atividades 
biológicas e acelera o processo de cicatrização, foi testado o efeito adjuvante dos péptidos 
CRAMP e P-LL37 para efeitos de vacinação, usando a protease Sap2 de Candida albicans como 
antigénio. Além disso, foi avaliado o efeito da aplicação tópica de LL37 nas feridas de ratinhos 
diabéticos. Estas experiências estão descritas no capítulo 5. A administração de CRAMP ou P-
LL37 juntamente com Sap2 não aumentou a produção de anticorpos específicos anti-Sap2. Isto é, 
não foi detectada atividade adjuvante para nenhum dos dois péptidos. A aplicação tópica de LL37 
nas feridas de ratinhos diabéticos não acelerou o processo de cicatrização de maneira muito 
significativa. No entanto, as análises histológicas das feridas após 13 dias revelaram dados 
encorajadores. De facto, estas análises mostraram que as feridas tratadas com LL37 eram 
menores e apresentavam vários anexos de pele que poderão originar novos pêlos, traduzindo 
uma mais eficiente regeneração dos tecidos.  
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1.1  Antimicrobial Peptides 
 
The increasing bacterial resistance against common antibiotics is a growing concern for 
the public health. Resistance began to emerge as early as the 1950s with multiresistant 
microorganisms such as Staphylococcus aureus, Pseudomonas aeruginosa or 
Enterococcus sp., in large part as the result of antibiotic overuse [1]. The exposition of 
living organisms to potentially harmful microorganisms is constant through contact, 
ingestion and inhalation [2]. Survival involves several levels of host defense mechanisms 
and the contact with microorganisms originates different reactions [3]: 
A. The invading microorganisms are eliminated by innate host defense 
mechanisms without inflammatory response; 
B. The host defenses are crossed over and innate immune system molecules are 
upregulated. These have direct antimicrobial activity and attract inflammatory 
cells and cells of the adaptive immune system resulting in the elimination of the 
microorganisms; 
C. Microbes surpass innate and adaptive immunity. The consequences are a 
strong inflammatory response and death of the host. 
Much research has been dedicated to the development of new classes of antibiotics to 
overcome bacterial resistance; research focusing on the structures and functions of 
antimicrobial peptides (AMPs) has greatly increased in recent years. AMPs are an 
important part of the innate immune system of most living organisms against invading 
pathogens with direct antimicrobial and mediator function. They play an important role in 
all the situations described above by providing the initial host defense mechanism. They 
are generally defined as peptides of less than 50 amino acids residues with positive 
charge, due to multiple lysine and arginine residues and with 50% or more of hydrophobic 
residues [4]. In addition to positively charged AMPs, peptide antibiotics with a negative 
charge at neutral pH have also been identified [5, 6]. Some of these peptides seem to 
originate as cleavage products from larger proteins. AMPs have aroused great interest 
due to their broad spectrum of antimicrobial activity against Gram-positive and Gram-
negative bacteria [7], fungi [8] and protozoa [9] with minimum inhibitory concentrations 
(MIC) as low as 0.25-0.4 !g/ml [10]. Certain cationic peptides have been shown to inhibit 
the replication of enveloped viruses such as influenza A virus [11], vesicular stomatitis 
virus (VSV) and human immunodeficiency virus (HIV-1) [12]. Moreover, these peptides 
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have potential to overcome bacterial resistance [2]. Therefore, AMPs or their derivatives 
can represent potentially new classes of antimicrobial drugs. 
1.1.1 Classification and source of antimicrobial peptides 
AMPs are found in all forms of life including bacteria, fungi, plants, insects, birds, 
crustaceans, amphibians and mammals and a single animal can contain different classes 
of peptides [13]. So far, more than 1700 peptides have been identified 
(http://aps.unmc.edu/AP/main.php). They can be divided into two classes based on the 
mechanism of their cellular synthesis: non-ribosomally synthesized and ribosomally 
synthesized peptides [14]. The first class is largely produced by bacteria and some are 
already used for clinical applications: polymyxin B and colistin (polymyxin E, colimycin) 
have been developed mainly for topical applications. Cyclosporin is widely used as 
immunosupressor. The non-ribosomally synthesized tripeptide ACV is the precursor of 
penicillin and cephalosporins [15]. Ribosomally synthesized peptides are produced by all 
organisms (including bacteria) as an important component of their host defense. 
Ribosomally synthesized AMPs are gene-encoded peptides, meaning that one gene 
codes for one peptide. AMP genes of vertebrates have a characteristic intron-exon 
structure with regulatory elements in their promoter regions (figure 1.1). The primary 
translational product is a prepropeptide consisting of an N-terminal signal sequence for 
targeting to the endoplasmic reticulum, a pro-segment, and a C-terminal cationic peptide 
that has antimicrobial activity after cleavage (figure 1.1). The pro-segment is generally 
anionic and may have several biological functions such as assisting the correct folding of 
the C-terminus, intracellular trafficking or inhibition of the activity of the mature peptide. 
AMPs are stored in cells as propeptides or mature C-terminal peptides [15]. 
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Figure 1.1. Gene of a vertebrate antimicrobial peptide and processing. The C-terminus represents the 
part of the molecule with antimicrobial activity: the "-defensin. The gene is represented schematically 
(adapted from Koczulla et al. [15]). 
 
AMPs can be grouped according to their size, conformational structure or predominant 
amino acid sequence; nevertheless, the diversity of these molecules is so great that it is 
difficult to categorize them in a generally accepted classification. On the basis of their 3D 
structure, peptide antibiotics can be classified in four major groups, with the first two 
being the most common in nature [10]: 
•   Group I: "-sheet structures stabilized by disulfide bridges. 
•   Group II: linear peptides with a #-helical structure. 
•   Group III: extended peptides. 
•   Group IV: peptides with loop structures. 
The representative structures from each of these classes are illustrated in figure 1.2. 
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Figure 1.2. Structural classes of antimicrobial peptides: (A) "-sheet, tachyplesin I; (B) #-helical, 
magainin 2; (C) extended, indolicidin; (D) loop, thanatin. Disulfide bonds are indicated in yellow (picture 
from Powers et al. [4]). 
 
AMPs from insects and other invertebrates 
A better understanding of the peptide production in response to pathogenic invasions 
came from the fruit fly, Drosophila melanogaster. Infection in this insect rapidly induces 
the production of a lineage of peptides namely drosomycin, cecropins, diptericin, 
drosocin, attacin and metchnikowin by the fat body cells [16]. Cecropins are 3, 4 kDa 
linear amphipathic peptides with activity against protozoa, metazoan parasites, bacteria 
and fungi [17]. Drosomycin and metchnikowin are potently antifungal while others exhibit 
antibacterial properties [18]. In certain species such as the ant, Pachycondyla goeldii, 
about 15 different peptides demonstrating antibacterial and insecticidal properties have 
been isolated from its venom. These peptides, named ponericidins, range from 1.8 to 3.3 
kDa and share sequence similarities with cecropins, mellitins and dermaseptins [19]. 
Insect defensins from various species have been characterized. These peptides are 
generally composed of 34–46 amino acid residues with exception of the 51-residue 
defensins characterized in bees [20]. All insect defensins share a consensus motif of six 
cysteines which form intramolecular disulfide bonds and all have the same cysteine 
pairing: Cys1-Cys4, Cys2-Cys5 and Cys3-Cys6 [16]. So far, many more AMPs from 
insects (188) have been identified. Table 1.1 summarizes some examples of insect AMPs 
that can be divided in the following groups: 
• The cysteine-containing peptides namely insect defensins, drosomycin, 
cecropins, sapecins and thanatin; 
• The proline-rich peptides like drosocin, lebocins and formaecins;  
• The gloverins (holotricins, diptericins), glycine-rich molecules. 
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Table 1.1. Antimicrobial peptides from insects (adapted from Reddy et al. [2] and Bulet et al. 
[16]) 
Source Peptide 
Number of amino 
acids 
Antibacterial 
activity 
Stomoxys calcitrans Smd 1 
Smd 2 
46 
40 
G+, G- 
G+, G- 
Drosophila melanogaster Drosomycin 
Drosocin 
Diptericin 
Metchnikowin 
44 
19 
83 
26 
F 
G$ 
G$ 
F 
Phormia terranovae Defensin-# 40 G+, G- 
Sarcophaga peregrina Sapecin-# 
Sapecin-" 
Sapecin-c 
40 
34 
40 
G+, G- 
G+, G- 
G+, G- 
Aedes aegypti Defensin-# 
Defensin-" 
40 
40 
G+, G- 
G+, G- 
Apis mellifera Mellitin 
Defensin 
Royalisin 
26 
51 
51 
G+, G-, H 
G+, G- 
G+, G- 
Acalolepta luxuriosa Acaloleptin 71 G+, G- 
Hyalophora cecropia Cecropin 37 G- 
Lycosa carolinensis Lycotoxin 27 G+, G- 
Cupiennius salei Cupiennin 35 G+, G- 
Podisus maculiventris Thanatin 21 G+, G- 
Tenebrio molitor Tenicin 1 43 G+, G- 
Bomby mori Lebocin 1 
Lebocin 2 
Lebocin 3 
32 
32 
32 
G+, G- 
G+, G- 
G+, G- 
Myrmecia gulosa Formaecin 1 
Formaecin 2 
16 
16 
G- 
G- 
Holotrichia diomphalia Holotricin 3 84 F 
G+: gram-positive; G-: gram-negative; F: antifungal; H: haemolytic. 
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Apart from insects, other invertebrates possess antimicrobial peptides. Tachyplesins, 
17,18 amino acid long peptides isolated from the haemocytes of the Japanese horseshoe 
crab, Tachypleus tridentatus, are bactericidal against Gram-positive and Gram-negative 
bacteria [21]. Polyphemusin, an isoform of tachyplesin has been purified from the 
haemocytes of Limulus polyphemus, a related horse shoe crab [22]. Both are cysteine-
rich peptides with similar sizes and intramolecular disulfide-pairing patterns. Another 
peptide, a defensin with 8 kDa, was purified from the haemocyte granules of T. 
tridentatus [23] showing significant homology with mammalian "-defensin.  
Androctonin, a 25-residue AMP has been isolated from the scorpion Androctonus 
australis by Ehret-Sabatier et al [24]. This highly cationic peptide has four cysteine 
residues involved in the formation of two intramolecular disulfide bridges and is active 
against Gram-positive and Gram-negative bacteria and fungi. Penaeidins, peptides with 
47 to 62 residues, were purified from shrimps by Destoumieux and colleagues [25] and 
Cuthbertson et al. [26]. These AMPs exhibit activity against Gram-positive bacteria and 
filamentous fungi but not against Candida albicans or Saccharomyces cerevisiae [27].  
 
 
AMPs from plants 
 
Plants are constantly exposed to a large variety of microorganisms, such as viruses, 
fungi, bacteria, protozoa, mycoplasma and nematodes [28]. The survival in these 
conditions requires quick defense mechanisms, which include the synthesis of defense 
peptides and proteins with antimicrobial properties. The major groups of AMPs in plants 
are thionins and defensins.  
The thionins are basic peptides (pI>8), with low molecular weight (~5 kDa), rich in basic 
and sulfur-containing residues (arginine, lysine and cysteine). They share high sequential 
and structural similarities besides presenting toxic effects against bacteria, fungi, yeast, 
animal and plant cells. Purothionins are basic polypeptides with antimicrobial properties 
that are present in the endosperm of wheat and other cereal species. Antimicrobial 
activity was demonstrated in phytopathogenic bacteria such as: Pseudomonas, 
Xanhtomonas, Erwinia e Corynebacterium [29]; yeast [30] and phytopathogeninc fungi 
[31]. Besides their activity against microorganisms, Carrasco et al. [32] described 
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cytotoxic activity of thionins on mammalian cells. Several in vivo functions have been 
proposed for thionins, like the regulation of proteins [33, 34]. 
Plant defensins were initially known as %-thionins because they showed a similar size (5 
kD) and the same number of disulfide bridges (four) as #- and "-thionins. They were 
isolated in the 90s from wheat, barley, sorghum, radishes and other species of 
Brassicaceae [28]. Later, it was concluded that the %-thionins actually show a low degree 
of similarity with other thionins. Therefore, Broekaert et al. [35] suggested to include the 
%-thionins into a superfamily of antimicrobial peptides, with representatives in vertebrates, 
invertebrates and plants, renaming them as plant defensins. Plant defensins are 45 to 54 
amino acids long, have a net positive charge, and show clear, although relatively limited, 
sequence conservation. Many plant defensins present a powerful fungicide action [35], 
but bacteria are mostly unaffected, with some exceptions such as Bacillus subtilis [36], 
Pseudomonas solanacearum and Clavibacter michigansis [37].  
 
AMPs from animals 
 
AMPs in animals are expressed in several tissues, polymorphonuclear leukocytes, 
macrophages and mucosal epithelial cells; they can also be secreted into circulating 
fluids (e.g. the bloodstream or the haemolymph), which deliver AMPs to infection sites.  
Some examples of antimicrobial peptides from animals are listed in table 1.2, according 
to their structure. The two major groups of AMPs in mammals are defensins and 
cathelicidins.  
Mammalian defensins are cationic, relatively arginine-rich, nonglycosylated peptides with 
a molecular weight of 3.5-4.5 kDa and contain six cysteines that form three characteristic 
intramolecular disulfide bridges [38]. According to their structure, defensins can be 
divided into three classes: #-defensins, "-defensins and &-defensins [15].  
#-Defensins are 29-35 amino acids long, contain three disulfide bridges in a 1-6, 2-4, 3-5 
alignment and reveal a triple stranded "-sheet structure with a "-hairpin, which contains 
cationic amino acids. At the present time, six human #-defensins have been identified. 
Human neutrophil peptides 1-4 (HNP 1–4) are found in the azurophil granules of 
neutrophils. The two other human #-defensins 5 and 6 (HD 5–6) are primarily found in 
Paneth cells of the small intestine. They are active at 1-100 !g/ml against Gram-positive 
bacteria, Gram-negative bacteria, mycobacteria, fungi and enveloped viruses [39]. 
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Table 1.2. Antimicrobial peptides from animals (adapted from Koczulla et al. [15]) 
Peptide Species, organ Activity 
Group I: !-sheet structures stabilised by two or three disulphide bridges 
Protegrin Pig, intestine Antimicrobial 
Defensins Vertebrates, immune cells, 
epithelia 
Antimicrobial, 
chemoattractant 
&-Defensins Monkeys, neutrophils Antimicrobial 
Group II: Linear, "-helical peptides without cysteines 
Bombinins  Frog, skin Antimicrobial 
LL-37 Human, neutrophils, epithelial 
cells 
Antimicrobial, 
chemoattractant, wound 
healing, angiogenesis 
Magainins Frog, skin Antimicrobial 
Group III: extended peptides 
PR-39 Pig, intestine, neutrophils Antimicrobial, 
angiogenesis, wound 
healing 
Bac5, Bac7 Cow, neutrophils Antimicrobial 
Group IV: Peptides with loop structures 
Bactenecin Cow, neutrophils Antimicrobial 
Ranalexin Frog, skin Antimicrobial 
 
"-Defensins have 36-42 residues and are arginine-rich with broad antimicrobial, antiviral 
and cytotoxic activity. Although there is low sequence homology with #-defensins, their 
tertiary structure is very similar. Therefore, this new family of AMPs was named "-
defensins. "-defensins reveal a disulfide alignment of 1–5, 2–4, 3–6, and have been 
isolated from several species [40]. The first human "-defensin, called human "-defensin 1 
(hBD-1), was originally isolated from haemofiltrate of patients undergoing dialysis 
treatment and is expressed constitutively in epithelial cells of the urinary and respiratory 
tract [41]. Human "-defensin 2 (hBD-2) was isolated from psoriatic skin and is widely 
expressed in epithelia, leukocytes and the bone marrow [42]. hBD-3 was isolated from 
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human lesional psoriatic scales and cloned from keratinocytes [43]. Schuttle et al. 
identified 28 new human and 43 new mouse "-defensin genes in five syntenic 
chromosomal regions by screening human and murine genome databases [44].   
A novel class of defensins, were isolated from rhesus monkey neutrophils and named &-
defensins according to their circular molecular structure [45].  
Besides their antimicrobial activity, defensins possess other properties like antitumoral 
activity, cells proliferation, chemoattraction of immune cells, stimulation of cytokines and 
expression of adhesion molecules [40]. 
Cathelicidins are a family of antimicrobial peptides derived from proteins, that contain a 
highly conserved signal sequence and pro-region but show substantial heterogeneity in 
the C-terminal domain. Because of the similarity of their proregions to cathelin, a 12 kDa 
protein from porcine leukocytes, this family of antimicrobial peptides was named 
cathelicidins [46]. The C-terminal domain that encodes the mature peptide with 
antimicrobial activity can range from 12 to 97 amino acid residues. To date, cathelicidins 
have only been found in mammals, in the neutrophils of horses, cattle, pigs, sheeps, 
rabbits and mice. They are particularly abundant in porcine and bovine neutrophils [47]. 
The only human cathelicidin, LL-37 or hCAP-18, was isolated from human bone marrow 
[48]. The processing of cathelicidin preforms to mature antimicrobial peptides occurs by 
proteolytic cleavage of the propiece upon degranulation of neutrophils. This cleavage is 
mediated by elastase in cattle and pigs and proteinase 3 in humans [47]. Cathelicidins 
have a diverse range of antimicrobial activity against Gram-negative and Gram-positive 
bacteria [49], fungi [50, 51], parasites [52, 53] and enveloped viruses [54]. In mammals, 
cathelicidins with #-helical, extended or loop structure, and "-sheet peptides with 2 or 3 
disulfide bridges have been identified [47].  
Cathelicidins have first been identified for their antimicrobial activities; however, additional 
biological functions have been documented. These activities include wound repair 
mechanisms, chemoattractant properties that recruit inflammatory cells, induction of 
angiogenesis, interaction with lipopolysaccharides (LPS), and induction of cytolysis [47]. 
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1.1.2 Functions of AMPs 
 
Antimicrobial activity 
The antimicrobial activity of peptide antibiotics was deduced from in vitro tests against 
microorganisms. AMPs have a broad-spectrum activity against Gram-positive and Gram-
negative bacteria as well as against fungi and enveloped viruses. The minimal inhibitory 
concentrations of the more effective peptides are in the range from 0.1–10 µg/ml. AMPs 
show synergistic activity with other host defense molecules, such as lysozyme and 
lactoferrin. 
The exact mechanism by which AMPs exert their antimicrobial properties is yet unclear, 
but it is generally accepted that cationic AMPs interact by electrostatic forces with the 
negatively charged bacterial membrane phospholipids, leading to its disruption. In the 
case of microbes, the anionic lipids are present on the outer surface of the membrane 
whereas for mammalian cells, anionic lipids are present along the cytoplasmic side of the 
membrane. This feature might account for their preferential activity against bacteria. 
Another major difference in the membranes chemical composition that distinguishes 
prokaryotic and eukaryotic cells is that the latter are abundant in sterols. The presence of 
membrane-stabilizing cholesterol has been shown to protect human erythrocytes from 
magainin 2 [55]. Among the several mechanisms proposed, the most widely accepted are 
the “barrel-stave”, “carpet” and “toroidal” models [56].  
The “barrel-stave” model describes the formation of transmembrane channel/pores by 
groups of amphipathic #-helical peptides, where the hydrophobic surfaces interact with 
the aliphatic chain of the membrane phospholipids and the hydrophilic parts point inside 
producing an aqueous pore [57]. This pore formation can be confirmed by stepwise 
conductivity increases in channel measurement. The transmembrane pore formation 
involves the binding of peptide monomers to the membrane in a helical fashion, followed 
by insertion of the helices into the hydrophobic core of the membrane. Progressive 
recruitment of additional monomers increases the pore size leading to leakage of cell 
contents and thereby death of the cell (Figure 1.3A). Pore formation accompanies the 
reorientation of the helix from the parallel state to the perpendicular membrane spanning 
state.  
In the “carpet model”, peptides accumulate on the bilayer surface. This model explains 
the activity of antimicrobial peptides such as ovispirin that orientate parallel (‘in-plane’) to 
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the membrane surface [58]. In the “carpet model”, peptides accumulate on the bilayer 
surface. Peptides are electrostatically attracted to the anionic phospholipid head groups 
at numerous sites covering the surface of the membrane in a carpet-like manner. At high 
peptide concentrations, surface-oriented peptides are thought to disrupt the bilayer by 
acting like a detergent, eventually leading to the formation of micelles [59]. 
 
 
Figure 1.3. Mechanisms of antimicrobial activity. A – Barrel-stave model; B – Carpet model; C – 
Toroidal model. Hydrophilic regions of the peptide are shown coloured red, hydrophobic regions of the 
peptide are shown coloured blue (adapted form Brogden et al. [56]). 
 
In the “toroidal-pore model”, antimicrobial peptide helices insert into the membrane and 
induce the lipid monolayers to bend continuously through the pore so that the water core 
is lined by both the inserted peptides and the lipid head groups. This type of 
transmembrane pore is induced by magainins, protegrins and melittin [60, 61]. The 
“toroidal” model differs from the “barrel-stave model” as the peptides are always 
associated with the lipid head groups even when they are perpendicularly inserted into 
the lipid bilayer. 
Dathe et al. [62] suggested that these mechanisms do not represent three completely 
different modes of action, but instead, there is a continuous graduation between them. 
Initially, the transmembrane potential and pH gradient are destroyed, the osmotic 
regulation is affected and respiration is inhibited [56]. 
The mechanism of bacterial killing by anionic peptides is not known. Anionic peptides 
require zinc for maximal activity and complex with it [63]. Brogden et al. [64] suggest that 
zinc may form a cationic salt bridge that allows the peptide to overcome the net negative 
charge on the microbial surface. Then, the peptide penetrates the outer membrane 
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without inducing any morphological changes [65]. Once in the cytoplasm, they may attach 
to ribosomes and inhibit ribonuclease activity, like aspartic acid polymers do, leading to 
the precipitation of cytoplasmic proteins. Killing occurs within 30 min [66]. 
Although the formation of ion channels, transmembrane pores and extensive membrane 
rupture eventually leads to the lysis of microbial cells, there is increasing speculation that 
these effects are not the only mechanisms of microbial killing. There is increasing 
evidence that antimicrobial peptides have other intracellular targets. Figure 1.4 illustrates 
the intracellular action of several AMPs from different sources. 
 
 
Figure 1.4. Mode of action for intracellular antimicrobial peptide activity. In this figure Escherichia coli is 
shown as the target microorganism (from Brogden et al. [56]). 
 
The action of cationic antimicrobial peptides is not limited to direct killing of 
microorganisms. Instead, they possess an impressive variety of additional activities that 
impact particularly on innate immune responses and inflammation. 
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Immunomodulatory properties 
Defensins and cathelicidins show chemoattractant properties on different cell types such 
as monocytes, T lymphocytes and dendritic cells (DC) [67]. Moreover, "-defensins induce 
the production of several chemokines and cytokines such as monocyte chemotactic 
protein-1 (MCP-1), macrophage inflammatory protein 3-# (MIP-3), RANTES, interleukin-6 
IL-6), IL-10, interferon-inducible protein 10, tumor necrosis factor # (TNF-#) and IL-1, 
mainly in keratinocytes. hBD-3 induces the higher expression of these cytokines and 
chemokines compared with hBD-1, -2, and -4 [68]. At low concentrations #-defensins 
induce the proliferation of fibroblasts and epithelial cells in the airways [69]. Also, 
defensins are able to induce phenotypic and functional changes in DC [70]. These 
experimental observations highlight the relevance of AMPs bridging the innate and 
adaptive immunity. Table 1.3 summarizes the effect of several AMPs on host cells and 
inflammatory/immune processes. LL37, the only human cathelicidin, also shows several 
immunomodulatory properties that will be discussed in more detail further ahead. 
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Table 1.3. Effect of cationic antimicrobial peptides on host cells and inflammatory/immune 
processes (adapted from Hancock and Diamond [13]) 
Peptide Effect Possible role in immunity 
LL37; PR-39; TAP; 
LAP; #- and "-
defensins 
Induction during inflammation Synthesis triggered by situations that 
might involve infection 
CAP11; Magainin 2 Promote histamine release from mast cells Stimulate increase in blood vessel 
permeability 
# -defensins  Induce IL-8 in airway epithelial cells Recruitment of neutrophils 
PR-39 Chemotactic activity for neutrophils; Induce 
cell surface matrix proteogylcans, syndecans 
1 and 4 
Increase phagocytic activity; Wound 
healing 
LL-37; HNP-1, -2 
and –3; histone 
H2B fragments  
Induction in wounds and blisters Wound healing 
Guinea-pig 
defensins 
Increased expression of CD11b,c and ICAM-
1 
Increase adherence of neutrophils 
Rabbit defensins 
NP-1,2 
Promote non-opsonic phagocytosis by 
macrophages 
Bacterial clearance 
Defensin I and II;  Inhibit fibrinolysis by tissue plasminogen 
activator 
Bacterial clearance; activation of 
macrophages 
Defensin; SB-37 Stimulate mitogenic effect for fibroblasts and 
epithelial cells; stimulate fibroblast growth 
Wound healing 
Histatin 3; pro Bac7 Inhibition of furin proprotein 
convertase/cathepsin L protease 
Inhibit tissue injury during 
inflammation 
BMAP-27; BMAP-
28; Lactoferricin 
Apoptosis in the U937 and RAW264.7 
macrophage lines and in in vitro- activated 
human lymphocytes 
Elimination of cells with intracellular 
bacteria, virus-infected cells and 
cancer cells 
Defensins Attenuates steroidogenesis Blunt the release of 
immunosuppressive cortisol during 
stress from infection; upregulated 
tissue inflammation 
ProBac7; defensins Chemotactic activity for monocytes Recruitment of monocytes, which 
differentiate into inflammatory 
macrophages 
Many peptides  Neutralize LTA responses in macrophages Antisepsis 
HNP-1, -2; LL-37 Chemotactic activity for T cells Recruit T helpers and initiate cellular 
immune responses 
Defensins; HNP-1, 
-2 and -3 
Enhancement of IFN-%, IL5, K6, K10 and 
proliferative responses by T-helper cells 
cytokine secretion, increased systemic IgG 
but not IgA 
Promotion of acquired systemic 
immune defenses (not mucosal 
immune defenses) 
Abbreviations: IFN, interferon; Ig, immunoglobulin; IL, interleukin; LAP, lingual antimicrobial peptide; LTA, 
lipoteichoic acid; LPS, lipopolysaccharide; TAP, transporters associated with antigen processing 
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1.1.3 AMPs as drugs 
AMPs have a number of potential advantages as future therapeutics. As already stated, 
in addition to their broad spectrum of antimicrobial activity and rapid killing of microbes, 
they neutralize endotoxin and are unaffected by classical antibiotic resistance 
mechanisms. Moreover, high levels of defensins have been reported in several 
pulmonary disorders such as idiopathic pulmonary fibrosis, alveolar proteinosis, acute 
respiratory distress syndrome, lung transplantation, and panbronchiolitis, among others 
[71]. The exact role of defensins in these lung disorders is not fully understood, but they 
are probably involved in the modulation of inflammatory response. Furthermore, Crohn's 
colitis is associated with an impaired induction of hBD-2 and hBD-3 [72]. Also, a deficient 
expression of #-defensins HD-5 and HD-6 in Paneth cells from patients with Crohn's ileal 
disease has been described [73].  
Several studies have demonstrated a cytotoxic activity of AMPs against cancerous cells. 
Three mechanisms have been proposed, namely: (1) lysis of the cell membrane, (2) 
activation of extrinsic apoptotic pathways, and (3) inhibition of angiogenesis [74]. Most 
research conducted in this field has centered on cecropins and magainins, but other 
AMPs like defensins, cathelicidin, and lactoferricin are also being studied.  
AMPs have proven to play an important role in wound repair and angiogenesis. 
Cathelicidins and defensins hBD-2 and hBD-3, rapidly and dramatically increase at the 
wound edges leading to wound repair. A recent study has shown that hBD-2 stimulates 
migration, proliferation and tube formation of endothelial cells in wounds, in vitro, leading 
to accelerated wound closure [75]. The induction of angiogenesis through the use of 
AMPs could generate new treatments to improve wound healing and to fight diseases. 
Having clearly a great potential, the tight regulation of AMPs should nevertheless be 
considered, since elevated amounts may lead to a chronic inflammatory process, as it 
has been demonstrated for psoriasis and rosacea [76, 77]. 
Due to their capacity to modulate both innate and adaptive immunity, considerable efforts 
have been made to exploit their therapeutic potential. Novel peptides for drug 
development are generally produced by modification of natural peptides. Table 1.4 shows 
some AMPs that have been or are currently being tested in clinical and preclinical trials. 
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Table 1.4. Companies involved in the development of antimicrobial peptides as drugs (adapted 
from Koczulla and Bals [15] and Guaní-Guerra et al. [78]) 
Company Name Peptide Clinical use 
Migenix MBI-226 
MX-594AN 
Catheter sepsis 
Acne 
Intrabiotics PG-1 Treatment of peritoneal infections caused by P. aeruginosa 
and S. aureus. Treatment of pneumonia. 
Novozymes Plectasin  Microbicidal activity against antibiotic-resistant bacteria 
Dermegen P-113 
D2A21 
Oral candidiasis, mucositis; lung spray 
Burn wounds, infected wounds 
Genaera Pexiganan (MSI-78) Infected diabetic food ulcers 
Xoma Corp. Neuprex  Meningitis 
Cubist 
Pharmaceuticals 
Daptomycin Sepsis 
AM Lactoferricin-B  Antifungal 
Entomed Heliomycin Antibacterial 
Trimeris Enfuvirtide (T-20) HIV 
 
The major problem of chemical synthesis for the production of AMPs is the elevated cost. 
It is possible to chemically synthesize most AMPs, but the costs exclude most peptides 
from clinical development. Therefore, biological expression strategies have been 
developed to circumvent this problem. Biological production routes using different 
microbial host systems such as bacteria, yeast and insect cells have been increasingly 
reported in recent AMP production studies [27, 79-84].  
In a different approach, the coding sequence of AMPs can also be transferred into the 
target cells by means of adenoviral gene transfer [85, 86]. Finally, the production of AMPs 
can be induced by stimulants administered by topic or systemic routes. Fehlbaum et al. 
[87] induced the expression of epithelial "-defensin with l-isoleucine and several of its 
analogs. This promising technique would avoid the possible toxicity and adverse systemic 
reactions, as well as the difficulty to deliver them in integral form to the desired sites of 
action [78].  
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1.2  Carbohydrate-Binding Modules (CBMs) 
as fusion partners 
 
Much research has been dedicated to AMPs as a new class of antibiotics. However, the 
chemical synthesis of these peptides carries high costs. Recombinant expression 
techniques for the large-scale production of AMPs can be much more viable 
economically, if the bio-production system is adequately optimized to increase the 
peptide expression yield while minimizing costs. Biological methods will also ease the 
production of peptides that require correct folding and disulfide bonds formation for 
antimicrobial activity (e.g. protegrin, &-, #- and "-defensin, bactenesin, and hepcidin), 
which is difficult to achieve using chemical synthesis due to the typical low amounts of 
correctly-oxidized products [88]. Unfortunately, the expression of heterologous genes in 
E. coli often fails due to the toxicity of the molecule of interest towards the host. This 
problem is particularly common in the case of antimicrobial peptides. Also, AMPs are very 
sensitive to intracellular proteases. The lethal effects of antimicrobial peptides on host 
(mostly E. coli) and proteolysis can often be circumvented by expressing the molecule of 
interest as part of a fusion protein (e.g. in conjunction with glutathione S-transferase 
(GST) [89] or thioredoxin [90, 91]).  
In recombinant expression systems, the purification of the proteins is generally the most 
critical step. Although very effective, chromatography is a slow process with high costs 
due to expensive matrixes. Therefore, fusion partners that would allow the 
overexpression of the AMPs and low purification costs are essential for the large-scale 
production of these peptides. 
Regarding their characteristics, carbohydrate-binding modules (CBMs) are promising 
fusion partners for the recombinant expression of AMPs.  
 
Many enzymes that hydrolyze insoluble carbohydrates share a common structure 
composed of a catalytic domain linked to an independent CBM. CBMs were initially 
classified as cellulose binding domains (CBDs), based on the initial discovery of several 
modules that bind cellulose [92, 93]. However, additional modules in carbohydrate-active 
enzymes that bind carbohydrates other than cellulose but that meet the CBM criteria are 
continually being found, hence the need to reclassify these polypeptides using a more 
Chapter 1|General Introduction 
 20 
inclusive terminology. CBMs are present in a large variety of enzymes, within a wide 
range of species, from archea, bacteria, viruses, fungi, plants and mammals. CBMs have 
affinity for crystalline cellulose, non-crystalline cellulose, chitin, "-1,3-glucans and "-1,3-
1,4-mixed linkage glucans, xylan, mannan, galactan and starch as well as cell-surface 
glycans [94]. A CBM is defined as a contiguous amino acid sequence within a 
carbohydrate-active enzyme with a discrete fold having carbohydrate binding activity [95]. 
They are classified into families based on amino acid sequence, binding specificity, and 
structure. The CAZy database provides an updated list of the CBM-containing proteins, 
arranged by CBM family. Actually, 64 families of CBMs have been identified 
(http://www.cazy.org/Carbohydrate-Binding-Modules.html#nb3 - June 2011).  
The CBMs are composed of 30 to about 200 amino acids and exist as a single, double, or 
triple domain in one protein. Their location within the parental protein can be both C- or 
N-terminal and is occasionally centrally positioned within the polypeptide chain [95]. 
CBMs can be found in both hydrolytic and nonhydrolytic proteins. Proteins that possess 
hydrolytic activity (e.g., cellulases and xylanases) are generally composed by a catalytic 
module and one or more CBMs that are normally joined by relatively unstructured linker 
sequences. The CBMs present in proteins that do not possess hydrolytic activity 
comprise part of a scaffolding subunit that organizes the catalytic subunits into a cohesive 
multienzyme complex known as a cellulosome. Cellulosomes are extracellular 
multiprotein complexes, first identified in the early 1980s on the anaerobic thermophilic 
bacterium Clostridium thermocellum [96]. It is composed of numerous kinds of cellulases 
and related enzyme subunits, which are assembled in a large non-catalytic protein that 
acts as a scaffoldin. The assembly of the cellulosome is facilitated by the high-affinity 
recognition between the scaffoldin cohesion and the enzymes dockerin molecules. 
Another scaffoldin module - the cellulose-binding domain - is responsible for binding to 
the substrate [97]. 
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According to the typology of the binding site CBMs, a classification in three types, A, B or 
C has been proposed [94]:  
• Type A: CBMs that bind to insoluble, highly crystalline cellulose and/or chitin. 
They display aromatic amino acid residues forming a planar hydrophobic surface 
that interacts with the glucosyl-pyranose ring of the substrate; 
• Type B: the largest type of CBMS that bind to less-ordered plant structural 
polysaccharides such as amorphous cellulose, mannan or xylan. The binding 
sites are extended, often described as grooves or clefts, and comprise several 
subsites able to accommodate the individual sugar units of the polymeric ligand; 
• Type C: these CBMs have a solvent-exposed binding pocket or blind canyon, 
small binding sites that interact with mono or disaccharides. 
 
CBMs have three general roles with respect to the function of their cognate catalytic 
modules [94]:  
• Proximity effect: they promote the association of the enzymes with the substrate, 
increasing their effective concentration; 
• Targeting function: they have selective substrate affinity, distinguishing different 
crystalline, amorphous, soluble and non-soluble polysaccharides; 
• Disruptive function: they can mediate non-catalytic disruption of fibers, 
rendering the substrate more susceptible to enzymatic hydrolysis. 
 
Many applications have been reported for CBMs, as reviewed by Moreira and Gama [98]. 
They have been used in the paper, textile and food industries; as probes for protein-
carbohydrate interaction and microarrays; as bioremediation and biomedical tools; they 
can also be used to modify physical and chemical properties of composite materials.  
Bioprocessing is the major application for CBMs, given that large-scale recovery and 
purification of biologically active molecules continue to be challenges for many 
biotechnological products. Biospecific affinity purification (affinity chromatography) has 
become one of the most rapidly developing divisions of immobilized affinity ligand 
technology. Several works describe the use of CBMs as a tag for recombinant protein 
purification [99-107]. Depending on the binding reversibility, different applications may be 
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envisaged. CBMs with reversible binding are powerful tools for low-cost affinity 
purification, while irreversible CBMs can be used for enzyme immobilization [108] or as a 
tool to adsorb bioactive peptides to carbohydrate-based materials [109, 110].   
The family 3 carbohydrate-binding module (CBM3) is the cellulose-binding module of the 
scaffolding protein CipA from C. thermocellum. It is a type A CBM and the crystal 
structure showed that its 155 amino acid residues fold into a single, compact domain that 
has an overall prismatic shape with approximate dimensions of 30Å'30Å'45Å. The 
CBM3 belongs to the all-" family of proteins and is arranged in two antiparallel " sheets 
that stack face-to-face to form a "-sandwich with jellyroll topology [111]. It has high 
affinity for cellulose with an equilibrium affinity constant (Ka) for Avicel of 7.7'106 M-1 
[112]. Guerreiro et al. have demonstrated that the CBM3 can be used as a successful 
fusion partner for recombinant expression in E. coli. The authors reported the high-level 
and soluble expression of four antimicrobial peptides fused to the CBM3 [100]. Moreover, 
the recombinant proteins retained the capacity to bind cellulose. Therefore, the use of 
CBM3 as fusion partner could permit the expression and purification of recombinant 
peptides by a fast and inexpensive method, using cellulose for purification. 
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1.3  The antimicrobial peptide magainin-2 
 
Frog skin has been used for medicinal purposes for centuries and is still used today in 
South American countries [113]. Magainins, a family of antimicrobial peptides present in 
the skin of the African clawed frog, Xenopus laevis, were first identified in 1987 by 
Michael Zasloff [114]. The author observed that it was extremely rare for non-sterile 
surgical wounds to develop infections in the microbially contaminated water-filled tanks to 
which the animals were returned immediately after surgery. Infections were not seen on 
the cut margins of the wound, at the sites of suture placement, or within the 
communicating subdermal space or peritoneum. He proposed that the antimicrobial 
peptides were responsible for the protection against infection characteristic of wound 
healing in this animal.  
These host defense peptides are secreted by granular glands in the skin of the frog in 
response to tissue injury and are also known as PGS-peptides (peptide beginning with 
glycine and ending with serine) [115]. Later, Kreil et al. reported that these peptides are 
expressed not only within the granular glands of the skin but also in the cells of the 
gastric mucosa and intestinal tract [116]. The generation of the antimicrobial peptides is 
achieved through proteolysis of longer peptide precursors that are presumably secreted 
on to the skin surface before cleavage.  
Magainins are cationic (+3 to +5) AMPs comprised of 21 to 27 amino acid residues that 
create an #-helical secondary structure characterized by separate cationic and 
hydrophobic faces. These peptides have been reported to have a wide spectrum of 
antimicrobial activities against Gram-positive and Gram-negative bacteria, fungi and also 
induce osmotic lysis of protozoa [114]. They are also known to facilitate wound closure 
and reduce inflammation [117]. The most important peptides that belong to this family are 
magainin-1 and magainin-2 (MAG-1 and MAG-2). Both AMPs are composed of 23 amino 
acid residues and only differ in two amino acids in the positions 10 and 22 with molecular 
weights of 2409.87 and 2466.93 Da respectively.  
  MAG-1: H2N-GIGKFLHSAG KFGKAFVGEI MKS-COOH 
  MAG-2: H2N-GIGKFLHSAK KFGKAFVGEI MNS-COOH 
cDNA analysis showed that MAG-1 and MAG-2 are both present in a single precursor 
protein of approximately 160 amino acids which contains one copy of MAG-1 and two 
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copies of MAG-2. Both AMPs are flanked by proteolytic cleavage sites, an arginine 
residue adjacent to the amino-terminal glycine and a lysine-arginine dipeptide adjacent to 
the carboxyl-terminal serine [114]. 
Magainin-2 has 4 lysines and 1 glutamate resulting in a positive charge of +3 at pH 7. 
The peptide is water soluble, unstructured and highly flexible in aqueous solution. 
However, MAG-2 forms an amphipathic #-helix in membrane environment [118]. The 
antimicrobial effect is attributed to the disruption of the bacterial membrane. MAG-2 
induces transmembrane pores that conform to the toroidal model [119]. At low solution 
concentrations, MAG-2 orients relatively parallel to the lipid bilayer surface. When the 
concentration increases, MAG-2 molecules insert into the lipid bilayer and adopt a 
transmembrane orientation [120]. The resulting pores lead to diffusion of intracellular ions 
and small molecules, which is followed by the collapse of the transmembrane 
electrochemical gradient and then microbial cell death. It has been shown experimentally 
that magainin-2 is about 5$10 times more potent than magainin-1. The MIC of MAG-2 
against most microorganisms is inferior to 100 !g/ml but the peptide is not haemolytic up 
to at least 150 !g/ml against human erythrocytes [121]. 
Magainins also possess antiviral properties. MAG-1 and MAG-2 exhibit inhibitory action 
toward Herpes Simplex Virus 1 and 2 (HSV-1 and HSV-2) at reduced and non-cytotoxic 
concentrations for epithelial cells (lower than 50 µg/mL) but are inactive against Junin 
Virus (JV) [122]. Recent works showed the capacity of MAG-2 to enhance transdermal 
delivery by perturbing stratum corneum lipids in the skin [123, 124]. Transdermal delivery 
is an attractive method to administer drugs that avoids the pain of injection, reduces the 
enzymatic degradation and facilitates sustained delivery for up to many days. Potent 
analogues of MAG-2 have been obtained by substitutions of glycine or serine with alanine 
residues, and an amidation at the C-terminus, which resulted in enhanced #-helical 
structure and antimicrobial activity. Studies with pronase digestion suggested that the 
higher antimicrobial activity may be due to differential susceptibility to proteolysis, in the 
presence of membranes [125]. Laughlin and Ahmad showed that MAG2-amide was able 
to inhibit ATP synthase by 60% in E. coli while MAG-2 reduced this activity by only 20% 
[126]. One of these potent analogues, magainin-A, showed spermicidal activity in vitro 
and in vivo. The minimum concentration of MAG-A required to immobilize spermatozoa 
within 20 seconds under in vitro conditions was 50 µg/mL in rat and 200 µg/mL in rabbits. 
However, in the case of monkeys the concentration required was five-fold higher 
compared to that of rabbits and the effect was found to be both time- and dose- 
dependent [127]. Monkeys are the only animal with a reproductive tract similar to that of 
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women, they are a suitable model for postcoital testing [128]. Therefore, Aranha et al. 
evaluated the contraceptive efficacy of MAG-A in monkeys as an in vivo model. The 
results indicated that 1 mg of MAG-A was sufficient to block completely sperm motility: 
none of the monkeys became pregnant as they returned to cyclicity in the following 
month. The repeated intravaginal administration of contraceptive doses of MAG-A caused 
no adverse effects on the morphology of vaginal epithelial cells or on hematologic and 
serum biochemical profiles [129]. However, Sengupta et al. recently reported that the 
administration of MAG-A in vitro resulted in attenuation of differentiation, enhancement in 
apoptosis and loss of viability in early placental villi trophoblast cells in primary culture 
and might adversely affect the process of placentation and pregnancy outcome [130]. 
In spite of great advances in cancer therapy, there is considerable current interest in 
developing anticancer agents with a new mode of action because of the development of 
resistance by cancer cells towards current anticancer drugs. A growing number of studies 
have shown that some AMPs exhibit a broad spectrum of cytotoxic activity against cancer 
cells. Such studies have considerably enhanced the significance of AMPs. MAG-2 shows 
cytotoxic activity against several human bladder cell lines with an average IC50 of 
approximately 200 µM but has no effect on normal murine or human fibroblasts [131]. 
Takeshima et al. reported that a magainin-2 derivative is able to permeabilize and cross 
the cell membrane of HeLa human cervical carcinoma cells [132]. MAG-2 and its more 
potent synthetic analogues (magainins A, B, and G) cause the rapid lysis of both 
hematopoietic and solid tumor cell lines at concentrations that are 5–10 fold lower than 
magainin concentrations that are lytic for normal human peripheral blood lymphocytes or 
neutrophils. Magainins lyse tumor cells by forming ion-conducting #-helical channels in 
the cancer cell membrane. Among the synthetic magainin analogues, magainin-G 
exhibited superior selectivity for human cancer cells whereas magainin-B is the most 
potent of the synthetic magainin analogues in terms of cytotoxicity [133]. Magainins A and 
G inhibit the growth of human small cell lung cancer cell lines, including drug-resistant 
tumor cell variants, with an average IC50 of approximately 9 µM. Also, MAG-A or MAG-G 
had an additive effect when used with the chemotherapeutic agents DDP and VP-16. 
effects. Two additional synthetic magainin analogues (MSI-136, comprised of L-amino 
acids and MSI-238, comprised of D-amino acids) were found to have superior in vitro 
cytotoxic activity against human lung carcinoma cells in comparison to native MAG-2 and 
to increase survival of ovarian teratoma-bearing mice. MSI-238 was more effective in vivo 
than MSI-136 or magainin-2, most likely because of decreased susceptibility to proteolytic 
degradation [134]. Soballe et al. demonstrated that MSI-511 (another synthetic all-D-
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amino acid magainin analogue) was more lytic for 17 human melanomas than for normal 
melanocytes. Moreover, the intratumoral injection of MSI-511 completely eradicated 
human melanoma cells grown as subcutaneous xenografts in immune-deficient mice 
[135]. MAG-2 only exhibits cytotoxicity at high concentrations probably because of the 
limited cell membrane-binding due to its low cationic charge. Therefore, one strategy for 
improving peptide binding is to increase the number of positive charges on the peptide by 
amino acid substitution or conjugation with a cationic peptide. Liu et al. [136] reported the 
enhancement of cytotoxicity of MAG-2 in tumor cells by conjugation with bombesin, a 14- 
amino acids peptide isolated from amphibian skin [137]. 
These activities, namely the antitumoral, make MAG-2 and analogues promising 
candidates for therapeutic applications.   
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1.4  The Human Cathelicidin LL37 
 
 
(“LL37, a human antimicrobial peptide with immunomodulatory 
properties” accepted for publication in the book titled: Science 
against microbial pathogens: communicating current research 
and technological advances) 
 
 
 
There are two major groups of antimicrobial peptides in humans: defensins and 
cathelicidins. All cathelicidins share a similar structure characterized by a highly 
conserved N-terminal domain of about 100 amino acid residues. This cathelin-like domain 
is flanked by a signal peptide (approximately 30 residues long) on its N-terminus, and by 
an antimicrobial peptide region on its C-terminus.  
 
1.4.1 Structure and cellular expression of LL37 
 
The only member of the cathelicidins family found to date in humans is LL37/hCAP18, an 
18 kDa peptide encoded by the gene CAMP (GeneBank ID 820). It was first described in 
1995 in bone marrow cells [138]. The name hCAP18 was chosen because of its close 
relationship to the cationic antimicrobial peptide found in rabbit, which has a molecular 
weight of 18 kDa and is therefore called Cationic Antimicrobial Peptide CAP18. The gene 
for the human cathelicidin hCAP18 is a compact gene of 1963 bp located in chromosome 
3, and is composed of four exons. Exons 1 to 3 code for the signal sequence and the 
cathelin domain, while exon 4 codes for the antimicrobial peptide [139] (figure 1.5).  
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Figure 1.5. Schematic structure of the LL37/hCAP18 gene and its processing into LL37 peptide.  
 
 
The mature antimicrobial peptide has 37 amino acid residues starting with two leucines 
(NH2-LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES-COOH), hence being named 
LL37.  It does not contain any cysteine or tryptophan residue and has a molecular weight 
of ~4.5 kDa. The peptide is derived by extracellular proteolysis of proteinase 3 from the 
C-terminal end of hCAP18 [140], differing from most cathelicidins that are cleaved by 
elastase [141, 142]. Initially, the active mature peptide was considered to be the 39-
residue FALL39, based on the presence of a typical KR cleavage site [143]. However, 
Gudmundsson et al. [139] used anti-FALL39 immunoglobulin to locate the mature peptide 
and isolated it from granulocytes after degranulation. The structural analysis determined 
the mature peptide to be LL37. Nevertheless, two research groups have described other 
processed peptides. Sorensen et al. reported that hCAP-18 in seminal plasma is 
processed to generate the 38-amino acid antimicrobial peptide ALL38 by the prostate-
derived protease gastricsin, when incubated at the vaginal pH. Indeed, ALL38 was found 
in the vagina following sexual intercourse and the antimicrobial activity of ALL38 against 
a variety of microorganisms tested was equivalent to that of LL37 [144]. Murakami et al. 
[145] and Yamasaki et al. [146] showed that after secretion onto the skin surface or 
sweat, the CAMP gene product is processed by a serine protease-dependent mechanism 
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into multiple novel antimicrobial peptides distinct from the cathelicidin LL37. These 
peptides (RK31, KS30, LL29, KS22 and KR20) showed enhanced antimicrobial action, 
acquiring the ability to kill skin pathogens such as Staphylococcus aureus and Candida 
albicans. 
At physiological pH, LL37 has a positive net charge of +6. The peptide has 6 lysines and 
5 arginines that carry 11 positive charges, while 3 glutamates and 2 aspartates residues 
bear 5 negative charges. It is relatively disordered in aqueous solution, but folds into an 
amphipathic !-helix in other environments, such as in contact with lipid membranes [147]. 
Guangshun Wang studied the structure of 13C,15N-labeled LL37 by three-dimensional 
triple-resonance NMR and reported that the helical region covers residues 2 to 30, while 
the C-terminus is mobile [148]. All antimicrobial peptides are amphipathic, meaning that 
they have hydrophobic and hydrophilic regions, allowing the electrostatic interaction with 
anionic bacterial membranes. Figure 1.6 illustrates the three-dimensional structure of 
LL37. The hydrophobic residues are shown in red and are aligned on one side of the 
peptide. 
 
 
Figure 1.6. #-helical structure of LL37. Hydrophobic residues are shown in red. 
 
LL37 and its precursor, hCAP18, are found at different concentrations in very different 
cells, tissues and body fluids, predominantly in leukocytes and various epithelial linings. 
But the expression of hCAP18/LL37 has been reported in many other tissues or body 
fluids like breast milk, sweat, wound fluids, saliva, gingiva, testis, spermatozoa, seminal 
plasma, amniotic fluids and more, as well summarized by Durr et al. [143]. In a recent 
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work, Laudien et al. also reported the expression of LL37 and defensins in the nasal 
epithelium providing a chemical defense shield [149]. AMPs are also present in ear wax 
preventing bacteria and fungi from causing infections in the external auditory canal [150]. 
The quantification of hCAP18/LL37 concentrations in vivo is challenging. Sorensen et al. 
developed a specific enzyme-linked immunosorbent assay (ELISA) for the detection of 
hCAP18 in cells, plasma and urine. They determined that the amount of hCAP18 in 
neutrophils is 0.627 !g/106 cells and is barely excreted in the urine. The plasma level is 
1.18 !g/ml, several fold higher than for other neutrophil specific granule proteins [151]. In 
the airway fluids, the levels of LL37 are estimated to be 2 !g/ml in adults and 5 !g/ml in 
neonates.  
The down and upregulation of LL37 have been identified in many diseases. A higher 
concentration of the peptide is more common in the presence of infections. In fact, in 
pulmonary infections the levels of LL37 are augmented two or three times [152]. A low 
expression of LL37 is associated with skin disorders like atopic dermatitis [153] or chronic 
ulcers [154]. Putsep et al. [155] reported that the neutrophils from patients with morbus 
Kostmann syndrome are deficient in LL37. However, in acute inflammation, LL37 
concentrations can dramatically increase, reaching 1.5 mg/ml in the skin lesions of 
psoriasis patients [156]. High concentrations of LL37 have also been associated to other 
inflammatory disorders like lupus erythematosus, contact dermatitis or inflamed synovial 
membranes [143, 157]. Gilliet and Lande [158] proposed that these inflammatory 
disorders are caused by the inappropriate recognition of self-nucleic acids with induction 
of interferon responses by plasmacytoid dendritic cells (pDCs). In normal conditions self-
DNA released by dying cells is unable to enter pDCs and is degraded rapidly by 
extracellular DNases. LL37 binds to self-DNA and forms aggregated particles that are 
resistant to degradation by DNases and able to enter pDCs through proteoglycan-
mediated attachment of LL37 to the cell membrane and lipid-raft-mediated endocytosis. 
Aggregated self-DNA particles are retained in early endocytic compartments to trigger 
induction of interferons (IFNs) by activating endosomal toll-like receptor 9 (TLR-9) as if 
they were viruses. Type I IFNs trigger local maturation of myeloid dendritic cell and 
activation of autoreactive T cells leading to the formation of psoriatic skin lesions. In this 
process, activated Th17 cells produce IL-22 and IL-17 that stimulate psoriatic 
keratinocytes to sustain the expression of cationic AMPs including LL37, which further 
forms complexes with self-DNA that is abundantly released in psoriatic skin lesions by 
apoptotic cells. As a result, LL37/self-DNA complexes constantly promote dendritic cell 
maturation and activation of autoreactive T cells, providing a self-sustaining feedback 
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mechanism that amplifies and maintains autoimmune skin inflammation in psoriasis. 
Leung et al. measured the serum concentrations of LL37 in eczema children patients and 
reported that the concentration of the peptide increased with the eczema severity. They 
considered that LL37 might be a biomarker for the severity of childhood eczema [159].  
The expression of LL37 is upregulated by several stimuli, such as pro-inflammatory 
cytokines, growth factors, nutrients, and bacterial products, especially at inflammation 
and repair sites. The mechanisms regulating the LL37 production are not fully 
understood. Recently, the roles of the vitamin D3 and the hypoxia response pathways in 
the regulation of LL37 production in leucocytes and keratinocytes have been described. 
Vitamin D3 is naturally produced in the skin during exposure to sunlight, and is activated 
by hydroxylases CYP27A1 and CYP27B1 to generate the biologically active 1,25-
dihydroxyvitamin D3 [158], which is a potent inducer of the antimicrobial protein 
cathelicidin in isolated human keratinocytes, monocytes, neutrophils and gingival 
epithelial cells [160-162]. As sunlight induces immunosuppression increasing the 
vulnerability to infection, Vitamin D3, potentially to balance this effect, stimulates the 
synthesis of LL37 in skin and circulating phagocytic cells [163]. Moreover, Hata et al. 
reported that oral administration of vitamin D for 21 days induced cathelicidin production 
in atopic dermatitis lesional skin [164].   
Hypoxia-inducible transcription factor 1# (HIF1#) also plays an important role in LL37 
cellular expression. In fact, HIF1#-null mouse neutrophils show a dramatic reduction in 
the levels of mouse cathelin-related antimicrobial peptide (CRAMP) [165]. Also, the 
siRNA knock down of HIF1# in human keratinocytes decreased the expression of 
hCAP18 [166]. On the other hand, Stroinigg and Srivastava [167] reported that the 
human beta-defensin 2 (HBD-2), present in significant amounts in human milk, greatly 
increased LL37 expression in colon and breast epithelial cells. Moreover, the exposure of 
human primary bronchial epithelial cells to IL-4 and IL-13 cytokines during mucociliary 
differentiation increased mRNA expression of hCAP18/LL37 and hBD-2 [168]. 
Finally, microorganisms can also regulate the expression of LL37. Bacterial products from 
both Gram-positive and Gram-negative bacteria were shown to increase LL37 production 
in cultured sinus epithelial cells [169]. Butyrate, a product of bacterial microflora in the 
colon, induces LL37 production [170]. LL37 cellular expression was also found to be 
augmented by Pseudomonas aeruginosa flagellin [171], fungal allergens in nasal tissue 
from chronic rhinosinusitis patients [172], and Helicobacter pylori in gastric epithelium 
[173]. On the other hand, other pathogens reduce the expression of the peptide: Shigella 
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flexneri suppress LL37 production [174]; Neisseria gonorrhoeae, a human pathogen 
causing the sexually transmitted disease gonorrhea, that preferentially attach to and 
invade epithelial cells of the genital tract was found to down-regulate the expression of 
LL37, indicating that pathogenic Neisseria may gain a survival advantage in the female 
genital tract by decreasing LL37 expression [175]; Cholera toxin and labile toxin, the 
major virulence proteins of Vibrio cholerae and enterotoxigenic Escherichia coli, 
respectively, are predominantly responsible for the suppression of LL37 and hBD-1 
expression in intestinal epithelial cells both in vitro and in vivo [176]. 
 
1.4.2 Functions of LL37 
LL37 was initially recognized for its antimicrobial properties. Nevertheless, it has been 
found to have additional defensive roles such as regulating the inflammatory response 
and chemo-attracting cells of the adaptive immune system to wound or infection sites, 
binding and neutralizing LPS, promoting re-epithelialization and wound closure and more 
as illustrated in figure 1.7.  
 
 
Figure 1.7. Biological activities of LL37. 
Chapter 1|General Introduction 
 33 
Antimicrobial activity 
The antibacterial activity of LL37 has mostly been studied in vitro using the synthetic 
peptide. The reported activities of LL37 vary in several studies, indicating that it is 
sensitive to differences in the experiment conditions, such as salt, pH and the phase of 
bacterial growth. Nevertheless, LL37 has a broad range of activity against both Gram-
negative and Gram-positive bacteria. LL37 exhibits potent activity against Escherichia 
coli, Salmonella typhimurium and Salmonella minnesota, Pseudomonas aeruginosa, 
Neisseria gonorrhoeae, Klebsiella pneumoniae and group A Streptococcus with MIC 
values of 0.6-7.6 µg/ml (0.1-2 µM) [177], 0.2-3.6 µg/ml (0.1-0.8 µM) [177], 0.9-5.7 µg/ml 
(0.2-1 µM) [177], 0.9 µg/ml (0.2 µM) [175], 4.2 !g/ml (0.9 !M) [178], and 5-72 µg/ml (1-16 
µM) [179] respectively, while low activity has been detected against the yeast Candida 
albicans (MIC >250 µg/ml or 56 µM) [180] and spirochaete (MIC>145 !g/ml or 32 !M) 
[181]. Besides its low activity against C. albicans, LL37 was still able to reduce the C. 
albicans infectivity by inhibiting its adhesion to plastic surfaces, oral epidermoid cells, and 
urinary bladders of female BALB/c mice. The inhibitory effects of LL-37 on cell adhesion 
and aggregation were mediated by its preferential binding to mannan, the main 
component of the C. albicans cell wall, and partially by its ability to bind chitin or glucan, 
which underlie the mannan layer [182].  LL37 has also been shown to possess some 
antiviral activity against herpes simplex virus [183] and vaccinia virus [184] and inhibits 
HIV-1 replication in peripheral blood mononuclear cells, including primary CD4(+) T cells 
[185]. Additionally, LL37 inhibits the formation of P. aeruginosa bacterial biofilms [186]. 
Like most other AMPs, LL37 kills microorganisms by membrane disruption, resulting in 
lysis. By using solid-state NMR data and differential scanning calorimetry, Wildman et al. 
proposed that LL37 covers the surface of the membrane, resulting in toroidal pore 
formation with subsequent leakage of the cytoplasmic content [187]. LL37 can also be 
cytotoxic to eukaryotic cells, including both erythrocytes and leukocytes. However, the 
cytotoxic concentrations (>58 µg/ml or 13 µM) are generally higher than the 
concentrations required for elimination of microorganisms [188].  
The MIC values of LL37 determined in vitro are similar with the physiological 
concentrations observed during infectious and inflammatory disorders. Several studies 
reported the antimicrobial activity of LL37 to be noticeably reduced in high salt 
concentrations, under serum conditions, in the presence of a lung surfactant preparation 
as well as in the presence of artificial tears. However, in vivo, LL37 acts together with 
other antimicrobial components, i.e. hBD-2 [76], lysozyme and lactoferrin [189], to show 
optimal killing capacity. Since the reported MIC values are determined for LL37 alone, 
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there might be an underestimation of the antimicrobial activity under in vivo conditions, 
where synergistic effect with other antimicrobial components has to be considered. In 
fact, the role of LL37 in disease has been demonstrated in several reports. Nizet et al. 
[190] showed that mice with disrupted Cnlp, the gene coding for CRAMP, bear increased 
susceptibility to skin infections. Since CRAMP is similar to LL37 in structure, tissue 
distribution and antimicrobial activity, the CRAMP knockout model is a useful one for 
studying the function of the human cathelicidin. The in vivo role of LL37 in preventing 
infections is also supported by an observation made in patients with morbus Kostmann 
syndrome. These patients lack LL37 in the saliva neutrophils, which may contribute to 
increased susceptibility to oral infections. A different approach to evaluate the role of 
LL37 in certain diseases is to overexpress the peptide. As example, an adenovirus vector 
was utilized to transfer the LL37-gene systemically or into trachea of mice [191]. 
Furthermore, the vector was inserted into human bronchial xenograft, derived from 
patients with cystic fibrosis [192]. The overexpression of LL37 augmented the killing of 
bacteria in all these cases. 
 
 
Lipopolysaccharide neutralizing properties 
Lipopolysaccharides (LPS) endotoxins are heteropolymeric components of the outer layer 
membrane of Gram-negative bacteria with strong immunotoxic properties. LPS play an 
important role in pathogenesis of many exogenous respiratory diseases, including 
organic dust toxic syndrome and chronic illnesses such as chronic obstructive pulmonary 
disease, asthma or allergic alveolitis (hypersensitivity pneumonitis) [193]. LPS is released 
upon cell death, activating mononuclear phagocytes (monocytes and macrophages) to 
produce and release proinflammatory cytokines such as TNF-#, IL-6, and others [194]. 
This event is initiated by binding of LPS to LPS-binding protein (LBP), followed by a 
second binding of the LPS-LBP complex to CD14, the primary receptor of LPS, which is 
expressed mainly on macrophages [195]. The LPS-CD14 complex initiates intracellular 
signaling by interacting with the transmembrane protein TLR-4, which activates the NF-
kB transcription factor, resulting in the production and secretion of pro-inflammatory 
cytokines [196]. The massive release of LPS can lead in extreme cases to endotoxic 
shock and therefore, death.  
Some AMPs, including LL37, have the capacity to neutralize LPS by binding it with high 
affinity, inhibiting LPS interaction with LBP and/or CD14 [197, 198]. Another mechanism 
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has also been suggested, where LL37 binds directly to CD14, inhibiting the association of 
LPS with its receptor. LL37 significantly inhibited the expression of specific 
proinflammatory genes upregulated by NF-kB in the presence of LPS in human 
monocytes [199]. It reduced TNF-# and nitric oxide levels produced by LPS and IFN-%-
polarized mouse bone marrow-derived macrophages [200]. Also, LL37 suppressed the 
LPS-induced apoptosis of endothelial cells [201]. Kandler et al. showed that LL37 also 
blocked the effect of flagellin and lipoteichoic acid on dendritic cells [202]. The 
antiendotoxic effect of LL37 has been confirmed in vivo using rat as a model system, 
making it a promising candidate for treatment of endotoxin shock or sepsis that is 
associated with a high rate of human death, for which there is yet no effective treatment 
[203]. 
 
 
Immunomodulatory properties 
In addition to its antimicrobial activity and ability to neutralize LPS, LL37 plays a central 
role in innate immunity. It is chemoattractant for mast cells [204], monocytes, T 
lymphocytes and neutrophils [205]. Formyl Peptide Receptor Like-1 (FPRL-1) is the only 
receptor found to activate direct migration of immunological cells to a site of infection. As 
leukocytes participate in both innate and adaptive immunity, the fact that LL37 can 
chemoattract human leukocytes may provide one additional mechanism by which LL37 
contributes to host defense against microbial invasion, by participating in the recruitment 
of leukocytes to sites of infection. This mechanism is potentially important in vivo, 
because the chemotactic activity of LL37, unlike its antimicrobial action, is not 
significantly inhibited by the presence of human serum. The activation of FPRL-1 requires 
relatively high concentrations of LL37 (10$5 M) when compared to other classical 
chemoattractant agents, suggesting a low-affinity peptide-receptor interaction [206]. This 
implies that cellular FPRL-1 mediated recruitment by LL37 in vivo may be active only 
when a threshold concentration of the peptide is reached following upregulation of the 
LL37 gene in epithelial cells or after massive release from invading neutrophils. 
Therefore, LL37 can potentially reach its optimal chemotactic concentration at local 
inflammatory sites. 
LL37 modulates cellular immune responses by stimulation of chemokine production. LL37 
activates airway epithelial cells as demonstrated by activation of the mitogen-activated 
protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) and increases release 
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of the potent chemoattractant IL-8. LL37 transactivates the epidermal growth factor 
receptor (EGFR) via metalloproteinase-mediated cleavage of membrane-anchored 
EGFR-ligands [207]. LL37 also induces IL-8 secretion through phosphorylation and 
activation of the MAPKs, extracellular signal-regulated kinase 1/2 (ERK1/2) in monocytes 
[208]. Human airway smooth muscle cells also respond to LL37 by releasing IL-8, 
suggesting that LL-37 is a regulator of the inflammatory process in various inflammatory 
lung diseases [209]. Yoshioka et al. [210] reported that LL37 also causes functional 
changes in mast cells. Mast cells in the skin are involved in the innate immune system 
response against microbial infections via Toll-like receptors, such as TLR-4, which that is 
known to recognize LPS. They observed that LL37 increased the level of TLR-4 mRNA 
and TLR-4 protein, and induced the release of IL-4, IL-5 and IL-1" from mast cells. 
Additionally, mast cells show degranulation upon stimulation with LL37. Degranulation 
releases pro-inflammatory mediators, such as histamine and prostaglandins, into the 
surrounding tissue, thus increasing vascular permeabilization and promoting the 
infiltration of inflammatory cells [211]. LL37 also interacts with the purinoceptor P2X7, 
predominantly expressed on monocytes, macrophages and DCs and induces the 
processing and release of the potent cytokine IL-1" [212] and IL-8 in human gingival 
fibroblasts [213].  
LL37 shows different effects on apoptotic cell death of different cell types. LL37 promotes 
apoptosis in various T-cells, smooth muscle cells and epithelial cells, while it is a potent 
inhibitor of human neutrophil apoptosis [188, 214]. The inhibition of neutrophils apoptosis 
may be a survival strategy, leading to an increase of viable neutrophils at the site of 
infection, which is beneficial for the host during bacterial invasion. It has been proposed 
that the underlying mechanism for the inhibition of apoptosis by LL37 is mediated via 
FPRL-1 and P2X7 receptors, resulting in the inhibition of caspase 3 activity [215]. Lau et 
al. [216] reported that the apoptosis of airway epithelial cells is inhibited by human serum. 
Finally, Davidson et al. [217] identified LL37 as a potent modifier of dendritic cells 
differentiation, bridging innate and adaptive immune responses. LL-37-derived DCs 
displayed significantly up-regulated endocytic capacity, modified phagocytic receptor 
expression and function, up-regulated costimulatory molecule expression, enhanced 
secretion of Th-1 inducing cytokines, and promoted Th-1 responses in vitro. Moreover, 
when internalized by immature human DCs, LL37 caused phenotypic changes, 
characterized by an increased expression of the antigen-presenting molecule HLA-DR, 
and the costimulatory molecule CD86 [218]. 
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Angiogenesis and wound healing 
The healing of wound is a complex process that involves different steps: haemostasis, 
inflammation, remodeling/granulation tissue formation and re-epithelialization. 
Angiogenesis is critical to wound repair. Newly formed blood vessels participate in 
provisional granulation tissue formation and provide nutrition and oxygen to growing 
tissues. Angiogenesis, in response to tissue injury, is a dynamic process that is highly 
regulated by signals from both serum and the surrounding extracellular matrix 
environment [219].  
LL37 is importantly involved in tissue healing processes, especially revascularization and 
cell growth. LL37 induces angiogenesis mediated by FPRL-1 expressed on endothelial 
cells. Koczulla et al. [220] reported that the application of LL37 stimulated 
neovascularization in a chorioallantoic membrane assay and in a rabbit model of hind-
limb ischemia. The peptide directly activates endothelial cells, resulting in increased 
proliferation and formation of vessel-like structures in cultivated endothelial cells. Also, 
decreased vascularization during wound repair was observed in mice deficient for 
CRAMP. LL37 induces wound healing, proliferation, and migration of airway epithelial 
cells. Therefore, the peptide is likely involved in the regulation of tissue homeostasis in 
the airways [221]. It also promotes the migration of keratinocytes via EGFR 
transactivation [222]. More importantly, upon injury, a large increase in the expression of 
cathelicidins in human and murine skin after sterile incision was observed and returned to 
normal levels as the wound closed [179]. The appearance of cathelicidins in skin was due 
to both synthesis within epidermal keratinocytes and deposition from granulocyctes that 
migrate to the site of injury. In human burns, higher mRNA levels of hCAP18/LL37, hBD-2 
and hBD-3 were detected [223]. The importance of LL37 in re-epithelialization was clearly 
demonstrated by Heilborn et al. [224]. The authors showed that the use of antibodies 
against LL37 inhibited re-epithelialization in a concentration-dependent manner in a non-
inflammatory ex vivo wound healing model and that the peptide is lacking in chronic 
ulcers. In a recent work, Carretero et al. [225] demonstrated that LL37 significantly 
improved re-epithelialization and granulation tissue formation by in vivo adenoviral 
transfer of the peptide to excisional wounds in ob/ob mice. According to Gronberg et al. 
the proteolytic environment of chronic wounds does not seem to prevent the therapeutic 
use of topical LL37. The authors showed that LL37 was not degraded by matrix 
metalloproteinase-9, and was fairly resistant to proteolytic cleavage ex vivo by incubation 
with wound fluid from non-healing venous leg ulcers [226].  
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As already stated, LL37 promotes cells proliferation and angiogenesis. Unfortunately, 
angiogenesis is also necessary for cancerous tumors to keep growing and spreading. 
LL37 has emerged as a novel modulator of tumor growth and metastasis in 
carcinogenesis in ovarian, lung, breast and prostate cancers [227-230]. In fact, LL37 
expression is upregulated in these tumors. However, in gastric cancer, the peptide 
inhibits cell proliferation [231]. LL37 also exhibits antitumor effects on epidermoid 
carcinoma cells, suggesting that the effect of LL37 on cancer phenotypes depends on the 
tissue origin of the tumor [232]. Although LL37 is demonstrated to promote cancer 
metastasis, fragments of the peptide have tumor inhibitory effects. These findings 
suggest that the fragments of LL37 have the potential to be developed into anticancer 
agents [233]. As an alternative strategy, LL37 has been shown to enhance the antitumor 
effects induced by CpG oligodeoxynucleotides (ODNs) through stimulating the tumor-
suppressing activity of natural killer cells [234, 235]. Unmethylated CpG sites can be 
detected by TLR-9 on pDCs and B lymphocytes in humans to detect intracellular viral, 
fungal, and bacterial pathogen DNA, resulting in the secretion of proinflammatory 
cytokines, which may contribute to the immune response to the pathogen [236]. The 
potent immunostimulatory effects of TLR-9 activation by CpG ODNs have resulted in 
enormous interest in the potential uses of these TLR-9 agonists as adjuvants for clinical 
therapy [237]. Hurtado and Peh reported that LL37 promotes the rapid sensing of CpG 
ODNs by B lymphocytes and pDCs but not T cells. These results are relevant to 
contemporary studies of TLR9 agonists as adjuvants for vaccines and cancer therapy 
[238]. 
 
 
LL37 is a multifunctional host defense peptide. Besides its antimicrobial activity, it 
stimulates a complex group of responses in many cells, either directly or through 
modulation of cellular responses to microbial compounds and other immune mediators. A 
better understanding of the biological activity of LL37 and its interactions with other 
immune mediators will permit to create strategies and opportunities for therapeutic 
intervention in infectious and inflammatory diseases. 
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1.5  Wound Healing 
 
Wound healing, or wound repair, is an intricate process in which the skin (or another 
organ-tissue) repairs itself after injury. Adult skin consists of two tissue layers: a 
keratinized stratified epidermis and an underlying thick layer of collagen-rich dermal 
connective tissue providing support and nourishment (dermis) [239]. Because the skin 
serves as a protective barrier against the environment, any break/injury sets in motion the 
wound healing process, characterized by four distinct, but overlapping phases: 
hemostasis (not considered by some authors), inflammation, proliferation and remodeling 
[240, 241]. The different phases of wound healing are represented in figure 1.8. 
 
Figure 1.8. The phases of normal wound healing. 
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Figure 1. The phases of cutaneous wound healing. (a) Immediately following cutaneous injury, blood
elements and vasoactive amines extravasate from locally damaged blood vessels within the dermis. Vascular
permeability is temporarily increased to allow neutrophils [polymorphonuclear neutrophils (PMNs)], platelets
and plasma proteins to infiltrate the wound. Vasoconstriction follows, in response to factors released by
these cells. (b) Coagulation then occurs as platelets aggregate with fibrin, which is deposited in the wound
following its conversion from fibrinogen. (c) Platelets release several factors, including platelet-derived growth
factor (PDGF) and transforming growth factor ! (TGF-!), which attract PMNs to the wound, signalling the
beginning of inflammation. (d) After 48 h, macrophages replace PMNs as the principal inflammatory cell.
Together, PMNs and macrophages remove debris from the wound, release growth factors, and begin to
reorganise the extracellular matrix. (e) The proliferation phase begins at about 72 h as fibroblasts, recruited
to the wound by growth factors released by inflammatory cells, begin to synthesise collagen. (f) Although the
rate of collagen synthesis slows down after about three weeks, collagen crosslinking and reorganisation
occur for months after injury in the remodelling phase of repair (fig001ktl).
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1.5.1 Hemostasis 
Most wounds to the skin will cause leakage of blood from damaged blood vessels. The 
formation of a clot then serves as a temporary shield protecting the denuded wound 
tissues and provides a provisional matrix over and through which cells can migrate during 
the repair process. The clot consists of platelets embedded in a mesh of cross-linked 
fibrin fibers derived by thrombin cleavage of fibrinogen, together with smaller amounts of 
extracellular matrix (ECM) proteins like plasma fibronectin, galectins, osteopontin, 
tenascins, thrombospondins and vitronectin [242].  
 
1.5.2 Inflammatory phase 
Platelets not only release the clotting factors needed to control the bleeding and loss of 
fluid and electrolytes but they also provide cytokines and growth factors, that initiate the 
healing response. The two most important signals are platelet-derived growth factor 
(PDGF) and transforming growth factor-beta (TGF-") [243]. The PDGF is involved in the 
chemotaxis of neutrophils, macrophages, smooth muscle cells and fibroblasts. In addition 
it also stimulates the mitogenesis of the fibroblasts and smooth muscle cells. TGF-" 
attracts macrophages and stimulates them to secrete additional cytokines including bFGF 
(basic fibroblast growth factor), PDGF, TNF-# and IL-1. In addition, TGF-" further 
enhances fibroblast and smooth muscle cell chemotaxis and modulates collagen and 
collagenase expression [241]. 
Polymorphonuclear neutrophils (PMNs) normally begin arriving at the wound site within 
minutes of injury. Neutrophils are the next predominant cell marker in the wound within 24 
hours after injury. The major function of the neutrophils is to remove foreign material, 
bacteria and non-functional (apoptotic) host cells and damaged matrix components that 
may be present in the wound site [244]. Neutrophils usually undergo apoptosis once they 
have completed their tasks and are, in turn, engulfed and degraded by macrophages 
[245].  
The mast cell is another marker cell of interest in wound healing. Mast cells release 
granules filled with enzymes, histamine and other active amines and these mediators are 
responsible for the characteristic signs of inflammation around the wound site [246]. 
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By 48 hours after injury, fixed tissue monocytes become activated to become wound 
macrophages that are essential for effective wound healing; if macrophage infiltration is 
prevented, then healing is severely impaired [247]. Macrophage tasks include 
phagocytosis of any remaining pathogenic organisms and other cell and matrix debris. 
Macrophages also secrete a number of factors such as growth factors and other 
cytokines. These factors attract cells involved in the proliferation stage of healing to the 
area, thus amplifying the earlier wound signals released by degranulating platelets and 
neutrophils. The growth factors involved in wound healing are described in table 1.5. At 
the end of the inflammatory phase the number of neutrophils and macrophages 
decreases and fewer inflammatory factors are secreted. The disappearance of 
macrophages is essential for the beginning of the next phase. In fact, Newton et al. 
showed that the presence of macrophages delayed wound contraction of an in vitro 
wound healing model [248].  
 
1.5.3 Proliferative phase 
The steps in the proliferative phase do not occur in a series but rather partially overlap in 
time. The proliferative phase is characterized by the formation of granulation tissue, 
epithelialization, and angiogenesis. As the proliferative phase progresses, the TGF-" 
released by the platelets, macrophages and T lymphocytes becomes a critical signal. 
TGF-" is considered to be a master control signal that regulates a host of fibroblast 
functions [249]. Granulation tissue consists of new blood vessels, fibroblasts, 
inflammatory cells, endothelial cells, myofibroblasts, and the components of a new, 
provisional ECM. TGF-" has a three-pronged effect on ECM deposition [250]. First, it 
increases transcription of the genes for collagen, proteoglycans and fibronectin thus 
increasing the overall production of matrix proteins. At the same time TGF-" decreases 
the secretion of proteases responsible for the breakdown of the matrix and it also 
stimulates the protease inhibitor TIMP - tissue inhibitor of metalloproteinase [251]. Other 
cytokines considered to be important are interleukins, bFGFs and TNF-# (Table 1.5). 
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Table 1.5. Growth factors involved in the wound healing process (adapted from Martin [239]) 
Growth factor Source Effects 
Epidermal growth factor  
(EGF)  
 
Activated 
macrophages 
Salivary glands 
Keratinocytes 
Keratinocyte and fibroblast mitogen 
Keratinocyte migration 
Granulation tissue formation 
 
Hepatocyte growth factor  
(HGF) 
Mesenchymal cells Epithelial and endothelial cell proliferation 
Hepatocyte motility 
Transforming growth factor 
(TGF-#)  
Activated 
macrophages 
T-lymphocytes 
Keratinocytes 
 
Hepatocyte and epithelial cell proliferation 
Expression of antimicrobial peptides 
Expression of chemotactic cytokines 
 
Basic Fibroblast growth factor  
(bFGF-1, -2 and -4) 
Macrophages 
Mast cells 
T-lymphocytes 
Endothelial cells 
Fibroblasts 
 
Fibroblast chemotaxis 
Fibroblast and keratinocyte proliferation 
Keratinocyte migration 
Angiogenesis 
Wound contraction 
Matrix deposition 
 
Keratinocyte growth factor 
(KGF) 
Keratinocytes 
 
Keratinocyte migration, proliferation and 
differentiation  
Platelet derived growth factor 
(PDGF)  
 
Platelets 
Macrophages 
Endothelial cells 
Smooth muscle cells 
Keratinocytes 
 
Granulocyte, macrophage, fibroblast and smooth 
muscle cell chemotaxis 
Granulocyte, macrophage and fibroblast activation 
Fibroblast, endothelial cell and smooth muscle cell 
proliferation 
Matrix metalloproteinase, fibronectin and 
hyaluronan production 
Angiogenesis 
Wound remodeling 
Integrin expression regulation 
 
Vascular endothelial growth 
factor (VEGF ) 
 
Keratinocytes; 
macrophages 
Angiogenesis 
Transforming growth factor-" 
(TGF-"1, -"2 and – "3) 
 
Platelets 
T-lymphocytes 
Macrophages 
Endothelial cells 
Keratinocytes 
Smooth muscle cells 
Fibroblasts 
 
Granulocyte, macrophage, lymphocyte, fibroblast 
and smooth muscle cell chemotaxis 
Fibroplasia 
Matrix metalloproteinase production inhibition 
Keratinocyte proliferation 
Antiscarring 
TIMP synthesis 
Interleukin-1 (IL-1# and –") 
 
Neutrophils 
 
Early activators of growth factor; expression in 
macrophages,keratinocytes, and fibroblasts 
Tumor necrosis factor-#  
(TNF-#) 
Neutrophils Early activators of growth factor; expression in 
macrophages,keratinocytes, and fibroblasts 
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The process of epithelialization is stimulated by the presence of EGF and TGF-# that are 
produced by activated wound macrophages, platelets and keratinocytes [241]. The 
epidermal covering is reconstituted from the edges of the wound and from the cut 
remnants of hair follicles [239]. Once the epithelial bridge is complete, enzymes are 
released to dissolve the attachment at the base of the scab (a hard coating on the skin 
formed during the wound healing reconstruction phase) resulting in its removal. The high 
metabolic activity at the wound site increases the demand for oxygen and nutrients. This 
is achieved through angiogenesis and stimulated by VEGF, bFGF, TGF-#, angiopoietin, 
and mast cell tryptase [252]. As already stated, LL37 is also an angiogenic factor that 
plays an important role in wound healing. 
Contraction is a key phase of wound healing and starts when fibroblasts have 
differentiated into myofibroblasts [253] that contain the same actin as smooth muscle 
cells [254]. As the actin in myofibroblasts contracts, the wound edges are pulled together 
and fibroblasts lay down type III collagen to reinforce the wound [240].  
 
1.5.4 Maturation and remodeling 
At the end of the granulation phase, fibroblasts begin to commit apoptosis, converting 
granulation tissue from an environment rich in cells to one that consists mainly of 
collagen [240]. At least 23 individual types of collagen have been identified to date but 
type I is predominant in the scar tissue of skin. Type III collagen is prevalent during 
proliferation but it is gradually degraded and the stronger type I collagen is laid down in its 
place [255]. In normal tissue collagen is a strong and highly organized molecule. 
However, collagen fibers formed in scar tissue are much smaller and have a random 
appearance. Therefore, the scar tissue is always weaker and will break apart before the 
surrounding normal tissue. The regained tensile strength in a wound will never approach 
normal. In fact, the maximum tensile strength that a wound can ever achieve is 
approximately 80% of normal skin [241]. Then, the activity at the wound site is reduced, 
and the blood vessels that are no longer needed are removed by apoptosis. Thus, the 
scar looses its red appearance [245]. Finally, in the process of collagen remodeling, 
collagen degradation also occurs [256].  
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1.5.5 Fibrosis and chronic ulcers 
Fibrosis can be defined as the replacement of the normal structural elements of the tissue 
by distorted, non-functional and excessive accumulation of scar tissue due to the 
aberrant production of cytokines [257]. Many clinical problems are associated with 
excessive scar formation. For example, keloids and hypertrophic scars in the skin, tendon 
adhesions, transmission blockage following nerve injury, scleroderma, Crohn’s disease, 
esophageal strictures, urethral strictures, capsules around breast implants, liver cirrhosis, 
pulmonary fibrosis, endomyocardial fibrosis atherosclerosis and fibrotic non-union in bone 
[241]. 
Keloids are a type of scar with an abnormal production of collagen. In fact, fibroblasts 
isolated from keloids produce about 2 to 3 times more collagen as compared to 
fibroblasts isolated from normal skin in the same patients [258]. Also TGF-" is expressed 
at greater levels in keloid fibroblasts when compared with normal human dermal 
fibroblasts [259]. Hypertrophic scars are also characterized by excessive accumulation of 
scar collagen. Contrary to keloids, hypertrophic scars regress in time. This can be 
explained by the presence of myofibroblasts in hypertrophic scars [260]. Fibrosis is also 
characterized by an augmentation of mast cells that contain specialized enzymes capable 
of processing procollagen [261]. 
Chronic non-healing dermal ulcers such as pressure ulcers contribute significantly to the 
morbidity and even mortality of many patients [262]. Wounds that do not heal within three 
months are often considered chronic. They generally remain in the inflammatory phase 
for too long. In fact, a biological marker of these wounds is the excessive infiltration of 
neutrophils. The neutrophils release significant amounts matrix metalloproteinases and 
elastase that are responsible for destruction of the connective tissue matrix and PDGF 
and TGF-" [263, 264]. These chronic ulcers will not heal until the chronic inflammation is 
reduced. 
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1.5.6 Diabetes mellitus impaired healing 
Diabetic foot ulcers, a leading cause of amputations, affect 15% of people with diabetes 
mellitus. The foot ulcer is a leading cause of hospital admissions for people with diabetes 
in the developed world and is a major morbidity associated with diabetes, often leading to 
pain, suffering, and a poor quality of life for patients [265]. Diabetes is the prototypical 
model of impaired wound healing. Several factors contribute to wound healing 
deficiencies in individuals with diabetes. These include decreased or impaired growth 
factor production, angiogenic response, macrophage function, collagen accumulation, 
epidermal barrier function, quantity of granulation tissue, keratinocyte and fibroblast 
migration and proliferation, number of epidermal nerves, bone healing, and balance 
between the accumulation of ECM components and their remodeling by matrix 
metalloproteinases [265]. 
Angiogenesis seems to be the most compromised phase in diabetes [266]. Several 
angiogenic growth factors such as bFGF and TGF-" have been described, but VEGF is 
unique for its effects on multiple components of the wound healing cascade, including 
angiogenesis and recently shown epithelialization and collagen deposition [267]. The 
impairment in VEGF synthesis and release at the wound site has been claimed as the 
crucial event for the altered production of new blood vessels. In fact, one of the 
mechanisms underlying the healing impairment in diabetic mice is thought to result from a 
defect in VEGF regulation, during gene expression [268]. In agreement with these 
observations, therapeutic interventions aimed at restoring the impaired VEFG production 
have succeeded in ameliorating the wound healing process in experimental model of 
diabetic mouse [269-272]. Therefore, the restoration of the angiogenesis process seems 
fundamental to reduce impaired healing in diabetes. As already stated, the AMP LL37 
promotes angiogenesis in vivo and in vitro and is important for re-epithelialization [220, 
224]. Thus, the therapeutic use of this peptide for the treatment of impaired wound 
healing should be considered.   
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Abstract 
Magainin-2 (MAG2) is a polycationic antimicrobial peptide isolated from the skin of the 
African clawed frog Xenopus laevis. It has a wide spectrum of antimicrobial activities 
against Gram-positive and Gram-negative bacteria, fungi and induces osmotic lysis of 
protozoa. MAG2 also possesses antiviral and antitumoral properties. These activities 
make this peptide a promising candidate for therapeutic applications. Recombinant 
expression systems are necessary for the affordable production of large amounts of the 
biologically active peptide. In this work, MAG2 has been cloned to the N- and C-termini of 
a family III carbohydrate-binding module fused to the linker sequence (LK-CBM3) from 
Clostridium thermocellum; a formic acid recognition site was introduced between the two 
modules for chemical cleavage of the peptide. 
The recombinant protein MAG2-LK-CBM3 was expressed in Escherichia coli BL21 (DE3) 
and LK-CBM3-MAG2 in E. coli M15 (pREP4). The N-terminal MAG2 from the first 
construction was successfully cleaved and purified from the fusion partner LK-CBM3. 
However, the peptide showed no antibacterial activity against E. coli K12. The negatively 
charged C-terminal aspartic acid left from the acid cleavage may be the cause for the 
absence of antimicrobial activity. The expression of C-terminal MAG2 from the second 
construct was not successful. We believe that the peptide has suffered proteolysis during 
recombinant expression.  
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2.1  Introduction 
Bacterial resistance to antibiotics, first noticed back in the 1950s, is a growing concern for 
public health [1]. Due to their mechanism of action, the antimicrobial peptides (AMPs) 
represent an attractive alternative as human therapeutics. AMPs are part of the innate 
immune system and represent an important component of immune defense. They have a 
large spectrum of antimicrobial activities against Gram-positive and Gram-negative 
bacteria, fungi [2] and viruses like influenza A [3] or human immunodeficiency virus (HIV-
1) [4]. Moreover, certain peptides may possess anticancer activity [5]. AMPs are 
generally defined as cationic, amphipathic peptides, with less than 50 amino acids, 
including multiple arginine and lysine residues [6] and show inhibitory concentrations 
(MIC) as low as 0.25-4 µg/ml [7]. They are widely distributed in nature, from insects to 
plants and animal species; 1755 AMPs have been identified so far 
(http://aps.unmc.edu/AP/main.php; May 2011).  
Magainins are AMPs isolated from the skin of the African clawed frog Xenopus laevis [8]. 
Magainins are comprised of 21 to 27 amino acid residues that create an #-helical 
secondary structure characterized by separate cationic and hydrophobic faces [5]. 
Magainin-2 (GIGKFLHSAKKFGKAFVGEIMNS), a polycationic peptide with a net positive 
charge of 3, has been well studied for its killing action on various micro- organisms, as 
well as on tumor cells [9-11]. It acts by permeabilizing their membranes, either in a 
detergent-like manner or by making well-structured channels [12, 13]. Magainin-2 and its 
more potent synthetic analogues (magainins A, B, and G) cause the rapid lysis of both 
hematopoietic and solid tumor cell lines at concentrations 5–10 fold lower than those lytic 
for normal human peripheral blood lymphocytes or neutrophils [5]. 
Many bacterial and fungal enzymes that hydrolyze insoluble carbohydrates share a 
common structure composed of a catalytic domain linked to a carbohydrate-binding 
module (CBM). CBMs that are specific for insoluble cellulose (Cellulose Binding Domain 
– CBD) represent the predominant category. The CBMs can be grouped into distinctive 
families on the basis of amino acid sequence similarities [14]; 64 families of CBMs have 
been recognized so far (http://www.cazy.org/fam/acc_CBM.html; June 2011).  
Family-III CBDs normally comprise ~150 amino acids residues, have been identified in 
many different bacterial enzymes, and also in non-hydrolytic proteins [15]. Clostridium 
thermocellum produces a multi-enzyme complex of cellulases and hemicellulases, 
termed the cellulosome, which is assembled by the scaffoldin protein CipA. Binding of the 
cellulosome to the plant cell wall is driven by the action of the CipA family 3 CBM 
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(CBM3), which presents high affinity for crystalline cellulose [16]. CBM3 belongs to the 
all-" family of proteins and is arranged in two antiparallel " sheets that form a " sandwich 
with jellyroll topology [15]. 
Since AMPs are usually short peptides, chemical synthesis could be one approach for 
producing them. However, such an approach has not been practical due to its high cost. 
The recombinant expression of AMPs requires the use of fusion constructs to reduce the 
toxicity towards the expression host. In this work, the fusion of MAG2 with the CBM3 was 
attempted as an approach for the large scale production of AMPs.  
 
 
 
2.2  Materials and Methods 
2.2.1 Construction of expression vectors 
The gene encoding CBM3 fused to the endogenous CipA N-terminal linker sequence 
(LK) has previously been cloned in the expression vector pET-21a (Novagen), in our 
laboratory [16]. Two expression vectors were constructed with MAG2, either at the N-
terminal (MAG2-LK-CBM3) of the pET-21a vector or C-terminal (LK-CBM3-MAG2) of the 
pQE-30 vector (Figure 2.1). These two vectors were constructed to allow the cloning of 
MAG2 at the N- or C-termini of the LK-CBM3 while keeping a terminal His6-tag. 
The nucleotide sequence of MAG2 was engineered to allow codon optimization in E. coli. 
The sequences encoding the peptide were included in the primers in fusion with the gene 
of a family 3 CBM. The pET-21a-LK-CBM3 was used as template. For the MAG2-LK-
CBM3 construction, the following primers were used: 5’- GGA ATTC CAT ATG GGT ATT 
GGT AAA TTT CTG CAT AGC GCG AAA AAA TTT GGT AAA GCG TTT GTG GGT GAA 
ATT ATG AAC AGC GAT CCG ACA CCG ACC AAG GGA GCA -3’ (forward primer) and 
5’- CAC CTC GAG TTC TTT ACC CCA TAC AAG AAC -3’ (reverse primer). For the LK-
CBM3-MAG2 construction, the primers used were: 5’- CGC GGA TCC ACA CCG ACC 
AAG GGA GCA -3’ (forward primer) and 5´-C GAG CTC TTA GCT GTT CAT AAT TTC 
ACC CAC AAA CGC TTT ACC AAA TTT TTT CGC GCT ATG CAG AAA TTT ACC AAT 
ACC CGG ATC TTC TTT ACC CCA TAC AAG -3´(reverse primer). NdeI, XhoI (MAG2-
LK-CBM3), BamHI and SacI (LK-CBM3-MAG2) recognition sites are shown in bold. In 
order to allow the chemical cleavage with formic acid, proline and aspartate residues 
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were introduced (underlined). PCR reactions were performed using the DNA Polymerase 
VENT (Stratagene). The PCR reactions were performed as follows: preheating at 95ºC 
for 2 min, 30 cycles at 95ºC for 30s, 30s at 52ºC and 30s at 72ºC, followed by a final 
elongation stage at 72ºC for 10 min. The amplified products were recovered from 1% 
agarose gel, digested with NdeI and XhoI or BamHI and SacI and ligated into pET-21a or 
pQE-30 plasmids, respectively. The plasmids were sequenced to ensure that no 
mutations had occurred during the PCR. Figure 2.1 represents MAG2-LK-CBM3 and LK-
CBM3-MAG2 constructions.  
 
Figure 2.1. Schematic representation of MAG2-LK-CBM3 (A) and LK-CBM3-MAG2 (B) constructions. 
The AspPro site for chemical cleavage with formic acid is shown in black; H: His-tag. 
 
2.2.2 Expression and purification of fusion proteins 
The recombinant plasmid pET-21a-MAG2-LK-CBM3 was transformed into the E. coli 
strain BL21 (DE3) (Novagen) and pQE-30-LK-CBM3-MAG2 into E. coli M15 (pREP4) 
(Quiagen) for protein expression. The bacterial strains were grown in Luria-Bertani broth 
(LB) containing 100 µg/ml of ampicillin or 100 µg/ml of ampicillin plus 50 µg/ml of 
kanamycin, at 37ºC, to mid-exponential phase (OD595=0.6). Expression of the fusion 
proteins was initiated by adding isopropyl-"-D-thiogalactopyranoside (IPTG) at a final 
concentration of 1 mM and the culture was incubated overnight at 37ºC. The culture 
harboring E. coli M15 was incubated overnight at 25ºC after induction with IPTG 1 mM. 
The cells were centrifuged at 6000 rpm for 15 min at 4ºC, resuspended in Tris–HCl pH 
7.0, 20 mM NaCl, 5 mM CaCl2(2H2O) buffer (CBM buffer) and sonicated in ice for 6 min. 
H2N COOH MAG2 LK-CBM3 
A – pET-21a 
COOH H2N LK-CBM3 MAG2 
B – pQE-30 
BamHI SacI 
NdeI XhoI 
H 
H 
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The cells were centrifuged at 12000 rpm, for 30 min at 4ºC and the soluble fraction was 
collected.  
The His6-tagged recombinant proteins were purified by immobilized metal ion affinity 
chromatography (IMAC), using 5 mL Niquel His-Trap Columns (GE Health). The column 
charged with 0.1 M NiSO4 was equilibrated with 20 mM of Na3PO4, 500 mM NaCl, 40 mM 
Imidazole, pH 7.4. The cell extracts were loaded into the column, which was washed with 
the equilibration buffer. Finally the recombinant proteins were eluted with 20 mM Na3PO4, 
500 mM NaCl, 300 mM Imidazole, pH 7.4. After purification, proteins buffer was 
exchanged into CBM buffer, using PD10-columns (GE Health). 
The recombinant proteins were also purified on cellulose CF11 (Sigma), exploiting the 
CBM3 cellulose-binding properties, as follows: 20 ml of cell-free extracts were mixed with 
2 g of cellulose and incubated, with agitation, for 1h at 4ºC. The cellulose with bound 
proteins was then centrifuged and washed 5 times with CBM buffer. 
 
2.2.3 Formic acid cleavage and MAG2 purification 
In order to cleave MAG2 of the recombinant protein, a 50% formic acid solution (20 ml of 
distilled water and 26 ml 88% formic acid) was applied directly to cellulose with the 
adsorbed fusion proteins. In the case of proteins purified by IMAC, formic acid was mixed 
with the purified protein (20 ml of pure protein and 26 ml of formic acid 88%). The mixture 
was then incubated for 24h at 50ºC. The supernatant was separated after centrifugation 
at 12000 rpm, for 30 min, and lyophilized to remove formic acid. The cleavage was 
confirmed by SDS-PAGE using a 16.5% Tris-Tricine gel.  
The purification of MAG2 was achieved by reverse-phase HPLC, using an YMC C18 
preparative column (250'30 mm) equilibrated with aqueous acetonitrile (5%)/0.1% 
trifluoracetic acid (TFA). The peptide was eluted using a linear gradient of acetonitrile 
from 5% to 90% at a flow rate of 5 ml/min. The elution was monitored at 215 nm. Several 
peaks were collected and analyzed by SDS-PAGE using a 16% Tris-Tricine gel. The 
fraction corresponding to pure MAG2 was lyophilized.  
The purification of MAG2 was also attempted through ultrafiltration in a Centricon with 5 
kDa molecular weight cut-off (Millipore). The filtrate was collected and analyzed by 16% 
Tris-Tricine gel SDS-PAGE. 
The concentration of the recombinant peptides was quantified using Waddell’s method 
[17]. 
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2.2.4 MALDI-TOF mass spectrometry 
The formic acid cleavage of the recombinant proteins and the purity of MAG2 were 
evaluated by mass spectrometry at the Institute of Molecular Pathology and Immunology 
of the University of Porto (IPATIMUP). Samples were desalted and concentrated using 
microC18 ZipTips (Millipore, USA) accordingly to the manufacturer’s protocol. The 
samples were eluted with the matrix #-cyano-4-hydroxycinnamic acid (5 mg/mL) in 50% 
acetonitrile/0.1% TFA and spotted onto a stainless steel 192-well MALDI plate. After 
sample crystallization, mass spectrum acquisition was performed using a 4700 
Proteomics Analyzer MALDI-TOF/TOF (Applied Biosystems, USA). Mass spectra were 
acquired in positive linear mode for 1-15 kDa (m/z) mass window and in positive reflector 
mode for the ranges 700-7000, 4000-5000 and 4585-4600 Da (m/z). External calibration 
of the mass spectrum was performed using Applied Biosystems Calibration Mix 3 
standards. 
 
 
2.2.5 Antibacterial activity 
The antibacterial activity of the pure peptides was quantified in 96-well polypropylene 
microtiter plates, as described by Vogt et al. [18], with some modifications. E. coli strain 
K12 was grown at 37ºC in LB medium until mid-logarithmic phase (OD600=0.5). The cells 
were then resuspended in LB at 1'106 and 1'105 cells/ml; 100 µl of peptides, at different 
concentrations, were inoculated with 50 µl of bacterial suspension, incubated overnight at 
37ºC and the bacterial growth was assessed by the measurement of optical density at 
620 nm. Each assay was repeated three times and controls were made by adding sterile 
deionized water, instead of the peptide solutions.  
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2.3  Results and discussion 
 
2.3.1 Expression and purification of recombinant proteins 
The antimicrobial peptide MAG2 was successfully cloned at both the N- and C- termini of 
the LK-CBM3 in the expression vectors pET-21a and pQE-30. After transformation of the 
recombinant plasmids into E. coli BL21 (DE3) or M15 (pREP4), several fermentation 
conditions were tested, attempting to optimize the production of the recombinant proteins 
in the soluble form. The fusion protein MAG2-LK-CBM3 (~24 kDa) was successfully 
expressed in soluble form after induction at 37ºC with 1 mM IPTG (figure 2.2A). The 
optimal expression of the recombinant protein LK-CBM3-MAG2 (figure 2.2B) was 
achieved after induction with 1 mM IPTG at 25ºC.  
 
Figure 2.2. Expression of recombinant proteins MAG2-LK-CBM3 (A) and LK-CBM3-MAG2 (B). Mw, 
protein molecular weight marker; 1, before induction; 2, insoluble fraction; 3, soluble fraction. 
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There are two major problems in the expression of antimicrobial peptides in E. coli: the 
cytoxicity of the peptides to the host and the sensitivity of peptides with positively charged 
amino acids to proteases. The high toxicity of the peptides usually leads to expression in 
inclusions bodies or in aggregate form. To overcome this situation, the use of a fusion 
partner is highly recommended. Guerreiro et al. [16] reported the soluble expression of 
the family 3 CBM from C. thermocellum – also used in this work - fused to three different 
antimicrobial peptides: LKLLKKL, LKKLLKKLKKLLKK and porcine myeloid antibacterial 
peptide-23 (PMAP-23) RIIDLLWRVRRPQKPKFVTVWVR. Only the protein 
LKLLKKLLKLLKKLGGGK-LK-CBM3 was found to be insoluble when expressed by 
different E. coli strains, under a range of induction conditions. Therefore, the solubility of 
antimicrobial peptides fused to the CBM3 is rather unpredictable, but the expression of 
the fusion proteins was, in all cases, successful. In this work, the expression of soluble 
magainin-2, either at the N- or C-terminus of the LK-CBM3 protein, was achieved. The 
family 3 cellulose-binding module was chosen as fusion partner considering the 
previously demonstrated successful overexpression of several CBM-AMPs, and the 
simplicity of purification using cellulose as an affinity chromatography matrix. 
The recombinant proteins MAG2-LK-CBM3 and LK-CBM3-MAG2 were purified trough 
IMAC and on cellulose CF11 fibers.  Figure 2.3 illustrates the purification of MAG2-LK-
CBM3 on cellulose (3A) and the purification of LK-CBM3-MAG2 by immobilized metal ion 
affinity chromatography (3B). The two recombinant proteins were purified using both 
methods and the results were similar.  
 
Figure 2.3. A: purification of MAG2-LK-CBM3 on cellulose fibers. Mw, protein molecular weight marker; 
1, total fraction; 2, unbound protein; 3, first cellulose wash; 4, fifth cellulose wash; 5, bound protein 
eluted with 1%SDS. B: purification of LK-CBM3-MAG2 by IMAC. Mw, protein molecular weight marker; 
1, uninduced cells; 2, insoluble fraction; 3, soluble fraction; 4, column filtrate; 5 and 6, column washes; 
7, pure protein. 
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As demonstrated by Tomme et al., CBM3 binds cellulose with high affinity. In fact, the 
equilibrium affinity constant (Ka) for Avicel was reported to be 7.7'106 M-1 [19]. Figure 
2.3A shows that the fusion of the peptide MAG2 did not affect the binding to cellulose. 
However, the purification of the proteins was more efficient by IMAC. The MAG2-CBM 
and CBM-MAG2 proteins are expressed in the soluble form, which makes the purification 
on cellulose difficult to achieve due to unspecific binding of contaminating proteins.  
 
2.3.2 Chemical cleavage of MAG2-LK-CBM3 
Formic acid was chosen for hydrolysis instead of thrombin or factor Xa proteases, to 
reduce production costs. After purification, 50% formic acid was applied to cleave the 
AMP MAG2 from the fusion carrier, the CBM3. The results obtained for the two 
constructions were different. The formic acid cleavage of MAG2 (~2.5 kDa) from the 
fusion partner LK-CBM3 was successful, as illustrated in figure 2.4. After hydrolysis, the 
mixture was lyophilized to remove the formic acid. The proteins were resuspended in 
ultrapure water and centrifuged to remove proteins degraded by the formic acid. 
 
 
Figure 2.4. Formic acid cleavage of the recombinant protein MAG2-LK-CBM3. Mw, protein molecular 
weight marker; insoluble fraction of cleaved MAG2-LK-CBM3; 2, supernatant of cleaved MAG2-LK-
CBM3; 
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The figure 2.4 shows that a significant number of contaminants were present in the 
supernatant after the formic acid cleavage. Consequently, the supernatant containing the 
MAG2 peptide was purified by reverse-phase HPLC. The fractions corresponding to the 
major peaks (figure 2.5A) were collected and the purity of the peptide was checked on 
16.5% Tris–Tricine gel (figure 2.5B). 
 
Figure 2.5. A: Reverse-phase HPLC chromatogram of MAG2-LK-CBM3. B: RP-HPLC peak fractions. 
Mw, protein molecular weight marker; lanes 1–8, peak fractions of cleaved MAG2-LK-CBM3. 
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The fraction with a retention time of about 50 minutes (peak 7) contained the mostly pure 
antimicrobial peptide MAG2. Some contaminant proteins were not efficiently removed by 
RP-HPLC and remained present in low amounts. To confirm the purity and molecular 
weight of the peptide, MALDI-TOF analysis was performed (figure 2.6).  
 
Figure 2.6. MALDI-TOF MS analysis of purified MAG2. The measured molecular weight is very close to 
the predicted theoretical value (2582 Da). 
 
The peptide resulting from the hydrolysis has 24 amino acids with a C-terminal aspartic 
acid (MAG2-D), left by the chemical cleavage and a theoretical molecular weight of 2582 
Da. The MALDI-TOF analysis confirmed the molecular weight of the recombinant peptide 
as well as its purity. This molecular weight indicates that the N-terminal methionine from 
the translation process has been cleaved. Giglione et al. [20] reported that 55–70% of 
mature proteins are subjected to N-terminal Met excision and this was the case with 
MAG2-LK-CBM3. 
 
 
2.3.3 Antibacterial Activity of MAG2-LK-CBM3 
After the successful expression and purification of magainin-2, its activity was tested 
against E. coli K12. The evaluation of the concentration of MAG2 was attempted using 
the Waddell’s method [17] but no satisfactory results were obtained. The presence of 
other contaminants in the sample could cause an incorrect determination of the protein 
Chapter 2|Expression and Purification of mag2 
 76 
concentration. Nevertheless, since the presence of MAG2 was confirmed by SDS-PAGE 
and MALDI-TOF its antibacterial activity was tested. However the peptide showed no 
effect against E. coli K12. The sample was concentrated by a factor of about 3 fold by 
lyophilization, but no antibacterial effect was detected. We strongly believe that the 
negatively charged C-terminal aspartic acid, left from acid cleavage, is the cause for the 
lack of activity. AMPs interact by electrostatic forces with the negatively charged bacterial 
membrane phospholipids, leading to its disruption. The lower net charge of the MAG2-D 
(+2) may suppress the antibacterial activity. Also, no bacterial activity was detected for 
the fusion protein MAG2-LK-CBM3. This result was somehow expected due to the mode 
of action of AMPs. In order to disrupt bacterial membranes, the peptides must reach a 
high peptide/lipid ratio to orientate perpendicularly and insert into the bilayer, forming 
transmembrane pores [21]. Gabriel et al. were able to prepare titanium surfaces with 
antimicrobial properties by grafting LL37. The application of a flexible hydrophilic 
poly(ethylene-glycol) spacer and selective N-terminal conjugation of LL37 resulted in a 
surface peptide layer which was capable of killing bacteria on contact [22]. However, 
since the CBM3 size is much larger than the linked AMP, the peptide/lipid ratio is 
probably unsuitable.  
 
2.3.4 Chemical cleavage of LK-CBM3-MAG2 
Given the negative results obtained with the MAG2-D peptide, a new construction was 
engineered. This construct made on the vector pQE-30, keeping a terminal His6-tag, was 
successfully expressed as shown above on section 2.3.1. After the purification of the 
fusion protein either on cellulose or by IMAC, the formic acid cleavage was performed as 
previously described and the samples were analyzed on 16.5% Tris-tricine gels. 
However, it was not possible to detect the antimicrobial peptide in the gels. Larger 
fermentations were made in order to increase the amount of fusion protein produced. 
After the chemical cleavage, the mixture was ultrafiltrated in a 5 kDa molecular weight 
cut-off Centricon to separate the peptide from the CBM3 and concentrated by 
lyophilization. Even so, we could not detect the peptide by SDS-PAGE.  
In order to better evaluate the cleavage process, MALDI-TOF analysis of the samples 
before and after hydrolysis were performed. The fusion protein LK-CBM3-MAG2 has a 
theoretical molecular weight of 24690 Da (including the C-terminal His6-tag). The MALDI-
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TOF analysis revealed a protein with molecular weight of 23974Da, below the theoretical 
expected value (figure 2.7). 
 
Figure 2.7. MALDI-TOF MS analysis of the fusion protein LK-CBM3-MAG2 before formic acid 
cleavage. 
 
Considering this result and the lack of detection of the peptide by SDS-PAGE analysis, 
we assume that the antimicrobial peptide MAG2 might have suffered proteolysis. Several 
fermentations conditions were tested; phenylmethanesulfonylfluoride (PMSF), a serine 
protease inhibitor, and protease inhibitor cocktail tablets (Roche) were used but similar 
results were obtained.  
To date, the successful cloning, expression and purification of the AMP magainin-2 in 
bacteria has not been reported. Barrell et al. reported the successful expression of MAG2 
fused to the well-known thioredoxin for raising antibodies [23]. However, they did not 
cleave and purify MAG2 from its partner. A magainin analogue (MSI-344) was expressed 
and purified in a good yield, but from E. coli inclusion bodies. The recombinant peptide 
kept its antibacterial activity [24, 25]. In a different approach, Fan and Li successfully 
expressed MAG2 in a mammalian cell system at high productivity and efficiency [26].  
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2.4  Conclusions 
The protein MAG2-D was successfully expressed cleaved and purified; however, the 
protein bears no antibacterial activity. On the other hand, when MAG2 was fused to the 
C-terminal of the CBM3 and transformed into E. coli M15 (pREP4) cells, proteolysis of the 
AMP was apparently observed. As already stated, the expression of AMPs in bacteria is 
challenging because they are sensitive to proteolytic degradation. Potent analogues of 
MAG2 have been obtained by substitutions of glycine or serine with alanine residues, and 
an amidation at the C-terminus, which resulted in enhanced #-helical structure and 
antimicrobial activity. Studies with pronase digestion suggested that the lower 
antimicrobial of MAG2 activity, when comparing to analogues, may be due to higher 
susceptibility to proteolysis in the presence of membranes [27]. The very few works 
reporting the expression and purification of MAG2 in E. coli may indicate that it is very 
difficult to produce MAG2 in bacteria. Interestingly, no such difficulties were observed in 
BL21 (DE3) in this work and by Guerreiro et al. [16].  
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Abstract 
 
The cathelicidin derived human peptide LL37 has a broad spectrum of antimicrobial and 
immunomodulatory activities. The large variety of biological activities makes LL37 a very 
promising candidate for clinical applications. The production of biologically active LL37 in 
large amounts with reduced costs can only be achieved using recombinant techniques. In 
this work, LL37 has been cloned to the N- and C-termini of a family III carbohydrate-
binding module fused to the linker sequence (LK-CBM3) from Clostridium thermocellum; 
both constructions (LL37-LK-CBM3 and LK-CBM3-LL37) were cloned into the pET-21a 
vector. A formic acid recognition site was introduced between the two modules, allowing 
the isolation of LL37 after chemical cleavage. 
The recombinant proteins were expressed in Escherichia coli BL21 (DE3) and solubilized 
with Triton X-100. The purification was achieved using cellulose CF11 fibers, taking 
advantage of the CBM3 specific affinity for cellulose; after hydrolysis with formic acid, 
LL37 was further purified by reverse-phase HPLC, as confirmed by MALDI-TOF mass 
spectrometry. The production and purification methodology developed in this work 
compares advantageously to other protocols previously described, having fewer 
purification steps. Only the recombinant LL37 obtained from the C-terminally fused 
protein (LK-CBM3-LL37) showed antibacterial activity against E. coli K12, with a MIC of 
180 !g/ml. 
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3.1  Introduction 
The increasing resistance of microorganisms against common antibiotics has become a 
growing threat for the public health. Antimicrobial peptides (AMPs) are part of the innate 
immune system and have a large spectrum of antimicrobial activities against Gram- 
positive and Gram-negative bacteria, fungi [1] and viruses [2]. AMPs are generally 
defined as cationic, amphipathic peptides, with less than 50 amino acids, including 
multiple arginine and lysine residues [3] and show inhibitory concentrations (MIC) as low 
as 0.25–4 !g/ml [2]. They are widely distributed in nature, from in- sects to plants and 
animal species; over 1440 AMPs have been identified so far 
(http://aps.unmc.edu/AP/main.php; July 2009). 
In mammals, defensins and cathelicidins represent the two major types of AMPs. 
Cathelicidins share a highly conserved N-terminal cathelin domain, flanked by a rather 
variable antimicrobial peptide on the C-terminus [4]. The hCAP-18/LL37 is the only 
human cathelicidin. The antimicrobial peptide is referred to as LL37, since it has a 37 
amino acids sequence starting with two leucines. It is a 4.5 kDa, cationic (+6), 
amphipathic a-helical peptide, with a broad spectrum of antimicrobial activity. LL37 and 
the precursor protein, hCAP-18, can be found at different concentrations in many different 
cells, tissues and body fluids. Durr et al. [5] summarized the various tissues where LL37 
expression has been detected. Besides its protective effect against infections, a variety of 
other biological activities have been described. In fact, LL37 induces chemotaxis of mast 
cells [6], monocytes, T lymphocytes and neutrophils [7], promotes wound healing [8], 
angiogenesis and arteriogenesis [9]. 
Many bacterial and fungal enzymes that hydrolyze insoluble carbohydrates share a 
common structure composed of a catalytic domain linked to a carbohydrate-binding 
module (CBM). CBMs that are specific for insoluble cellulose (cellulose binding domain – 
CBD) represent the predominant category. The CBMs can be grouped into distinctive 
families on the basis of amino acid sequence similarities [10]; 53 families of CBMs have 
been recognized so far (http://www.cazy.org/fam/acc_CBM.html; July 2009). 
Family III CBDs normally comprise !150 amino acids residues, have been identified in 
many different bacterial enzymes, and also in non-hydrolytic proteins [11]. Clostridium 
thermocellum produces a multi-enzyme complex of cellulases and hemicellulases, 
termed the cellulosome, which is assembled by the scaffoldin protein CipA. Binding of the 
cellulosome to the plant cell wall is driven by the action of the CipA family 3 CBM 
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(CBM3), which presents high affinity for crystalline cellulose [12]. CBM3 belongs to the 
all-" family of proteins and is arranged in two antiparallel " sheets that form a " sandwich 
with jellyroll topology [11]. 
In this work, we describe the successful cloning, expression and purification of LL37 
using the CBM3 from C. thermocellum as fusion partner. The CBM3 is overexpressed in 
Escherichia coli and it is possible to take advantage of its affinity properties to purify 
recombinant proteins on cellulose fibers, reducing significantly the costs of purification. 
 
 
3.2  Materials and Methods 
3.2.1 Construction of expression vectors 
The gene encoding CBM3 fused to the endogenous CipA N-terminal linker sequence 
(LK) has previously been cloned in the expression vector pET21-a (Novagen), in our 
laboratory [12]. Here, two expression vectors were constructed with LL37, either at the N-
terminus (LL37-LK-CBM3) or C-terminus (LK-CBM3-LL37) of the pET21-LK-CBM3 vector 
(Figure 3.1).  
The DNA fragment encoding LL37 was amplified by polymerase chain reaction (PCR) 
from hCAP-18/pET15b generously provided by Dr. Ole Sorensen, Lund University, Lund, 
Sweden. For the LL37-LK-CBM3 construction, the following primers were used: 5’- GGA 
ATTC CAT ATG CTG CTG GGT GAT TTC TTC-3’ (forward primer) and 5’- CTA GCT 
AGC CGG ATC GGA CTC TGT CCT GGG TAC-3’ (reverse primer). For the LK-CBM3-
LL37 construction, the primers were: 5’- CCG CTC GAG GAT CCG CTG CTG GGT GAT 
TTC TTC-3’ (forward primer) and 5´-CCG CTC GAG TTA GGA CTC TGT CCT GGG 
TAC-3´(reverse primer). NdeI, NheI  (LL37-LK-CBM3) and XhoI (LK-CBM3-LL37) 
recognition sites are shown in bold. In order to allow the chemical cleavage with formic 
acid, proline and aspartate residues were introduced (in italic). PCR reactions were 
performed using the DNA Polymerase VENT (Stratagene). The PCR reactions were 
performed as follows: preheating at 95ºC for 2 min, 30 cycles at 95ºC for 30s, 30s at 
52ºC and 30s at 72ºC, followed by a final elongation stage at 72ºC for 10 min. The 
amplified products were recovered from 1% agarose gel, digested with NdeI and NheI or 
XhoI and ligated into pET21-LK-CBM3 plasmid and sequenced to ensure that no 
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mutations had occurred during the PCR. Figure 3.1 represents LL37-LK-CBM3 and LK-
CBM3-LL37 constructions. The construction LL37-LK-CBM3 kept the C-terminal His6-tag 
even though this tag was not used for purification. 
 
Figure 3.1. Schematic representation of LL37-LK-CBM3 (A) and LK-CBM3-LL37 (B) constructions. The 
AspPro site for chemical cleavage with formic acid is shown in black; H, His-tag. 
 
3.2.2 Expression and purification of fusion proteins 
Figure 3.2 summarizes the strategy followed for the production and purification of 
recombinant LL37. The recombinant plasmids were transformed into the E. coli strain 
BL21 (DE3) (Novagen) for protein expression. The bacterial strains were grown in Luria-
Bertani broth (LB) containing 100 µg/ml of ampicillin at 37ºC to mid-exponential phase 
(OD595=0.6). Expression of the fusion proteins was initiated by adding isopropyl-"-D-
thiogalactopyranoside (IPTG) at a final concentration of 1 mM and the culture was 
incubated overnight at 37ºC. The cells were centrifuged at 6000 rpm for 15 min at 4ºC, 
resuspended in Tris–HCl pH 7.0, 20 mM NaCl, 5 mM CaCl2(2H2O) buffer (CBM buffer) 
and sonicated in ice for 6 min. After centrifugation at 12000 rpm, for 30 min at 4ºC, the 
cells were resuspended in CBM buffer with 1% Triton X-100. The cells were centrifuged 
again at 12000 rpm, for 30 min at 4ºC and the soluble fraction was collected.  
The recombinant proteins were purified on cellulose CF11 (Sigma), exploiting the CBM3 
cellulose-binding properties, as follows: 20 ml of cell-free extracts were mixed with 2 g of 
cellulose and incubated, with agitation, for 1h at 4ºC. The cellulose with bound proteins 
was then centrifuged and washed 5 times with CBM buffer. 
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Figure 3.2. Flow chart for the expression and purification of LL37 from E. coli. 
 
3.2.3 Formic acid cleavage and LL37 purification 
In order to cleave LL37 of the recombinant protein, a 50% formic acid solution (20 ml of 
distilled water and 26 ml 88% formic acid) was applied directly to cellulose with the 
adsorbed fusion proteins. The mixture was then incubated for 24h at 50ºC. The 
supernatant was separated after centrifugation at 12000 rpm, for 30 min, and lyophilized 
to remove formic acid. The cleavage was confirmed by SDS-PAGE using a 16.5% Tris-
Tricine gel.  
The purification of LL37 was achieved by reverse-phase HPLC, using an YMC C18 
preparative column (250'30 mm) equilibrated with aqueous acetonitrile (5%)/0.1% 
trifluoracetic acid (TFA). The peptide was eluted using a linear gradient of acetonitrile 
from 5% to 90% at a flow rate of 5 ml/min. The elution was monitored at 215 nm. Several 
peaks were collected and analysed by SDS-PAGE using a 16% Tris-Tricine gel. The 
fraction corresponding to pure LL37 was lyophilized. The concentration of the 
recombinant peptides was quantified using Waddell’s method [13].  
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3.2.4 MALDI-TOF mass spectrometry 
The purity of LL37 was confirmed by mass spectrometry at the Institute of Molecular 
Pathology and Immunology of the University of Porto (IPATIMUP). Samples were 
desalted and concentrated using microC18 ZipTips (Millipore, USA) accordingly to the 
manufacturer’s protocol. The samples were eluted with the matrix #-cyano-4-
hydroxycinnamic acid (5 mg/mL) in 50% acetonitrile/0.1% TFA and spotted onto a 
stainless steel 192-well MALDI plate. After sample crystallization, mass spectrum 
acquisition was performed using a 4700 Proteomics Analyzer MALDI-TOF/TOF (Applied 
Biosystems, USA). Mass spectra were acquired in positive linear mode for 1-15 kDa 
(m/z) mass window and in positive reflector mode for the ranges 700-7000, 4000-5000 
and 4585-4600 Da (m/z). External calibration of the mass spectrum was performed using 
Applied Biosystems Calibration Mix 3 standards. 
 
3.2.5 Antibacterial activity 
The antibacterial activity of the pure peptides was quantified in 96-well polypropylene 
microtiter plates, as described by Vogt et al. [14], with some modifications. E. coli strain 
K12 was grown at 37ºC in LB medium until mid-logarithmic phase (OD600=0.5). The cells 
were then resuspended in LB at 1'106 and 1'105 cells/ml; 100 µl of peptides, at different 
concentrations, were inoculated with 50 µl of bacterial suspension, incubated overnight at 
37ºC and the bacterial growth was assessed by the measurement of optical density at 
620 nm. The results were confirmed by plating 25 µl aliquots of the mixture from each 
well in LB plates and incubating for 16h at 37ºC, followed by colony counting. Each assay 
was repeated three times and controls were made by adding sterile deionized water, 
instead of the peptide solutions. The minimal inhibitory concentration (MIC) was 
determined as the lowest peptide concentration that inhibited bacterial growth.  
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3.3  Results and discussion 
 
3.3.1 Expression and purification of recombinant proteins 
 
The protein LL37 was successfully cloned at both the N- and C-terminus of the LK-CBM3 
in the expression vector pET21-a. After transformation of the recombinant plasmids into 
E. coli BL21 (DE3), several fermentation conditions were tested, attempting to optimize 
the production of the recombinant proteins in the soluble form. The following operational 
parameters and E. coli strains were varied or tested: concentration of IPTG, induction 
temperature and time, fermentation in M9 minimal medium, transformation into E. coli 
Tuner (DE3) and Origami (DE3) and co-expression with chaperones GroEL-GroES and 
E. coli trigger factor (TF) [15]. Only using the nonionic detergent, Triton X-100, the 
production of the proteins (~27 kDa) in the soluble form was achieved  (figure 3.3).  
 
 
Figure 3.3. Expression of recombinant proteins LL37-LK-CBM3 and LK-CBM3-LL37. Mw, protein 
molecular weight marker; 1, LL37-LK-CBM3 insoluble fraction; 2, LL37-LK- CBM3 soluble fraction; 3, 
LL37-LK-CBM3 Triton X-100 solubilized fraction; 4, LK- CBM3-LL37 insoluble fraction; 5, LK-CBM3-
LL37 soluble fraction; 6, LK-CBM3-LL37 Triton X-100 solubilized fraction. 
Mw 1 2 3 4 5 6 
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In previous work, Guerreiro et al. [12] reported the expression of the same CBM3 from C. 
thermocellum used in this work. The CBM, fused or not with small antimicrobial peptides, 
was overexpressed in the soluble form. Only the protein LKLLKKLLKLLKKLGGGK-LK-
CBM3 was found to be insoluble when expressed by different E. coli strains, under a 
range of induction conditions.  In this work, the CBM3 fused to LL37 could only be 
solubilized with detergents. The use of CBM3 as fusion partner had two major goals: (1) 
to express and purify the peptide LL37 by a novel, fast and inexpensive method, using 
cellulose for purification and (2) to modify the surface of cotton fabrics with LL37, aiming 
at obtaining textiles with antibacterial and bioactive properties. As already stated, LL37 is 
an antimicrobial peptide but it also has a broad spectrum of biological activities. Thus, 
one main objective was to modify cellulose for biomedical applications. However, in this 
work, we focus on the production of the isolated LL37. For this purpose, the CBM is still 
useful, allowing the separation of the recombinant protein through inexpensive affinity-
based separation, using cellulose fibers.  
The purification of the LL37-LK-CBM3 and LK-CBM3-LL37 recombinant proteins was 
performed on cellulose CF11 fibers. The family III CBM from C. thermocellum is well 
studied. This CBM adsorbs to cellulose with high affinity constants [16]. The fusion with 
LL37 and the presence of residual detergent did not affect the binding of the CBM3 on 
CF11 cellulose. Figure 3.4 shows a binding assay of the LK-CBM3-LL37 recombinant 
protein, performed as described previously [12]. The recombinant proteins bind very 
efficiently to cellulose and only desorb using SDS. 
 
Figure 3.4. Binding assay of LK-CBM3-LL37 on CF11 fibers. Mw, protein molecular weight marker; 1, 
Triton solubilized supernatant; 2, unbound protein; 3, first cellulose wash; 4, fifth cellulose wash; 5, 
bound protein eluted with 1% SDS. 
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To date, few groups have reported the recombinant expression of LL37 either in the E. 
coli expression system [17-19] or in the Pichia pastoris system [20]. In these publications, 
the purification of the recombinant proteins is always performed through affinity 
chromatography techniques, using expensive matrixes (sepharose, cobalt). Although very 
effective, chromatography is a slow process with high costs. LL37 is a peptide with a 
large potential for biomedical applications. Thus, the production of large amounts of LL37 
at low costs is of great importance, purification being generally the most critical step in 
this regard. Cellulose is cheap and available in many forms. Therefore, the expression 
system using the CBM3 as the expression and purification module is very attractive. As 
shown previously [12] and in this work, the CBM3, when fused to antimicrobial peptides, 
is overexpressed in E. coli conserving its binding properties. The adsorption of CBM3 on 
cellulose is quite fast, allowing the recombinant proteins to be purified in a quick, 
inexpensive method. Moreover, no columns and chromatography units are required. 
Compared with previous publications, this method is clearly the best for large-scale 
purification of LL37. 
 
3.3.2 Chemical cleavage and purification of LL37 
 
Several methods, both enzymatic (factor Xa and thrombin proteases) and chemical 
(CNBr and formic acid) are widely used to cleave proteins from fusion partners. Formic 
acid is a good option for large-scale production, due to its low cost. The chemical 
cleavage of the recombinant proteins was performed, in this work, with 50% formic acid, 
at 50ºC for 24h. LL37-LK-CBM3 and LK-CBM3-LL37 proteins were first purified on 
cellulose. Then, formic acid was applied directly on the CF11 fibers with the bound 
protein. After centrifugation, the supernatants were lyophilized to completely remove the 
acid and analyzed by 16.5% Tris-tricine gel (figure 3.5). 
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Figure 3.5. Formic acid cleavage and release of LL37. Mw, protein molecular weight marker; 1, 
insoluble fraction of cleaved LL37-LK-CBM3; 2, supernatant of cleaved LL37-LK-CBM3; 3, insoluble 
fraction of cleaved LK-CBM3-LL37; 4, supernatant of cleaved LK-CBM3-LL37. 
 
After acid hydrolysis and lyophilization, part of the protein (mostly CBM) precipitates, 
probably degraded by the formic acid. On the other hand, most of the peptide (~4.5 kDa) 
remains soluble, as shown in Figure 3.5 (lanes 2 and 4). The precipitation of the CBM3 
facilitates the purification. In fact, LL37 is separated from most of the CBM and other 
contaminating proteins by centrifugation. The soluble supernatants, with a large 
proportion of LL37, were then subjected to RP-HPLC to achieve higher purity (figure 
3.6a). In this step, the fractions corresponding to the major peaks were collected and the 
purity of the peptides was checked on 16.5% Tris-tricine gel and confirmed by MALDI-
TOF. Figure 3.6b presents the peak fractions from RP-HPLC for the two fusion proteins. 
Lanes 4 and 8 demonstrate the purity of the two peptides.  
Mw 1 2 3 4 
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Figure 3.6. A: Reverse-phase HPLC chromatogram of fusion proteins LL37-LK-CBM3 and LK-CBM3-
LL37. B: RP-HPLC peak fractions. Mw, protein molecular weight marker; lanes 1–4, peak fractions of 
cleaved LL37-LK-CBM3; lanes 5–8, peak fractions of cleaved LK-CBM3-LL37. 
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The two different proteins, both including the LL37, were obtained after the formic acid 
cleavage of the CBM constructs. The first peptide, obtained by the cleavage of the LL37-
LK-CBM3 protein, has 39 amino acids with a theoretical molecular weight of 4739.6 Da. It 
is flanked with the N-terminal methionine, remaining from the translation process and a 
C-terminal aspartic acid, left by the chemical cleavage (M-LL37-D). Although 55-70% of 
mature proteins are subjected to N-terminal Met excision [21], M-LL37-D conserved the 
initial amino acid. Indeed, as demonstrated by Sherman et al. [22] most proteins retain 
the initial Met when the N-terminus residue is leucine. The second peptide, cleaved from 
the LK-CBM3-LL37 protein, is 38 amino acids long, with a theoretical molecular weight of 
4590.4 Da, having a proline residue at the N-terminus (P-LL37). Mass spectrometry 
(figure 3.7) confirmed the purity of LL37 and the predicted molecular weights. 
 
Figure 3.7. MALDI-TOF MS analysis of purified LL37. A: M-LL37-D. B: P-LL37. The measured 
molecular weights are very similar to the theoretical values (4739.6 and 4590.4 Da). 
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The production and purification of LL37 using CBM3 as the fusion partner only requires 
one chromatographic step. All previous publications refer to at least two, and use 
enzymes to cleave LL37. Li et al. [17, 23] also use formic acid for chemical release of 
LL37, however the purification scheme used is more complex. In this work, it was 
possible to obtain 1 mg of pure P-LL37 and 2 mg of pure M-LL37-D from 1 liter of 
bacterial culture. This yield is comparable to the ones obtained in previous studies [17-
19]. Li et al. [23] also described a novel method to purify LL37 utilizing its property of 
aggregation. The authors were able to produce 2.6 mg of recombinant LL37 from 1 liter of 
culture. However, this method required two cleavage steps with thrombin and formic acid 
and three purification steps.  
 
3.3.3 Antibacterial activity 
 
M-LL37-D and P-LL37 antibacterial activities were tested against E. coli K12. The 
concentration of the peptides was quantified by UV spectroscopy using the Waddell’s 
method [13]. Figure 3.8 demonstrates that P-LL37 has antimicrobial activity, with a MIC of 
about 180 µg/ml (40 µM), similar to the values found in the literature [5, 17]. At lower 
concentration, P-LL37 inhibited bacterial growth only partially. The peptide (M-LL37-D) 
obtained from the N-terminal fusion construct (LL37-LK-CBM3) showed no antibacterial 
activity. According to Nagaoka et al. [24], the N-terminus and C-terminus of LL-37 do not 
contribute to the formation of #-helical structures, being less important for its antimicrobial 
activity. However, the C-terminal aspartic acid reduces the global charge of the peptide. 
Furthermore, Giglione et al. [21] suggest that an N-terminal Met may act as a 
destabilization signal. This peptide has a total charge of +5, so the second hypothesis 
seems to be more likely. In fact, other AMPs with lower net charge still exhibit 
antibacterial activity.  As already stated, recombinant LL37 has already been expressed 
and purified and E. coli but only two groups tested the antibacterial activity of the pure 
peptides. Yang et al. [18] produced the peptide GSLL-39 with a MIC of 12.5 µg/ml against 
E. coli DH5# and 25 µg/ml against S. aureus; Li et al. [17] obtained the peptide P-LL37 
with a MIC of 180 µg/ml (40 µM) against E. coli K12. Durr et al. [5] report that the MIC of 
LL37 against E. coli and S. aureus is higher than 144 µg/ml (32 µM), similar to the P-
LL37 expressed previously and in this work (figure 3.8). 
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Figure 3.8. Antibacterial activity of P-LL37 against E. coli K12. Bacterial growth was inhibited at a 
concentration of 180 !g/ml of P-LL37. 
 
 
 
3.4  Conclusions 
LL37 has been extensively studied in recent years. The variety of immunological and 
antimicrobial activities makes LL37 a very promising candidate for clinical applications. 
For these purposes, high amounts of affordable LL37 can only be obtained using 
recombinant techniques. Major advances in solid-phase chemical synthesis of peptides, 
over the last five years have rendered the large- scale synthesis of long chain-length 
bioactive peptides possible, but this technique is too expensive for the production of large 
quantities of pure peptides with more than 30 amino acids. In this work, the family III CBM 
from C. thermocellum was used as fusion partner, taking advantage of its cellulose-
binding properties for purification. The antibacterial assays showed that only P-LL37 was 
active. The methodology described in this work appears to be very effective for 
production and purification of AMPs. The use of cellulose for purification and formic acid 
for chemical cleavage make this method the more cost effective when comparing to 
previous publications. 
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Abstract 
 
Antimicrobial peptides (AMPs) are part of the innate immune system and are generally 
defined as cationic, amphipathic peptides, with less than 50 amino acids, including 
multiple arginine and lysine residues. The human cathelicidin antimicrobial peptide LL37 
can be found at different concentrations in many different cells, tissues and body fluids 
and has a broad spectrum of antimicrobial and immunomodulatory activities. The healing 
of wound is a complex process that involves different steps: haemostasis, inflammation, 
remodeling/granulation tissue formation and re-epithelialization. Inflammation and 
angiogenesis are two fundamental physiological conditions implicated in this process.  
We have recently developed a new method for the expression and purification of 
recombinant LL37. In this work, we show that the recombinant peptide P-LL37 with a N-
terminus proline preserves its immunophysiological properties in vitro and in vivo. P-LL37 
neutralized the activation of macrophages by lipopolysaccharide (LPS). Besides, the 
peptide induced proliferation, migration and tubule-like structures formation by endothelial 
cells. Wound healing experiments were performed in dexamethasone-treated mice to 
study the effect of LL37 on angiogenesis and wound regeneration. The topical application 
of synthetic and recombinant LL37 increased vascularization and re-epithelialization. 
Taken together, these results clearly demonstrate that LL37 may have a key role in 
wound regeneration through vascularization. 
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4.1  Introduction 
 
Cationic antimicrobial peptides (AMPs) represent the first line of defense against many 
invading pathogens. These small amphipathic peptides are part of the innate immune 
system and have a broad-spectrum activity against bacteria, fungi [1] and viruses [2].  
However, direct antimicrobial action is not the only, and probably not even the most 
important task of mammalian AMPs. In fact, these peptides present low antimicrobial 
activities under serum and tissue conditions [2, 3]. Nevertheless, they have affinity for 
lipopolysaccharide (LPS) and can prevent from lethal endotoxemia by suppressing 
cytokine production [4]. Moreover, these AMPs appear to be involved in the orchestration 
of many aspects of innate immunity and the inflammatory response [2]. 
In mammals, at least two distinct groups of AMPs are found. Defensins are the more 
representatives and cathelicidins form the second group of mammalian AMPs. 
Cathelicidins share a highly conserved N-terminal cathelin domain, flanked by a rather 
variable antimicrobial peptide on the C-terminus [5]. The hCAP-18/LL37 is the only known 
human cathelicidin. Upon stimulation, hCAP-18 is cleaved extracellularly by proteinase 3 
to generate the peptide LL37 [6]. The antimicrobial peptide is referred to as LL37, since it 
has a 37 amino acids sequence starting with two leucines. It is a 4.5 kDa, cationic (+6), 
amphipathic a-helical peptide, with a broad spectrum of antimicrobial activity. LL37 and 
its precursor hCAP18, were first described in leucocytes and testis, but were soon found 
in a large variety of cells, tissues and body fluids, as summarized by Durr et al. [7]. Upon 
injury or infection, there is a strong upregulation of hCAP18/LL37, indicating that LL37 
assists the immune system. The downregulation of LL37 has been associated to several 
diseases: a deficiency of LL37 in the skin of patients with atopic dermatitis [8] or chronic 
ulcers [9] may account for the increased risk for skin infections. Nizet et al. [10] showed 
that mice with disrupted Cnlp, the gene coding for CRAMP (cathelin-related antimicrobial 
peptide), showed increased susceptibility to skin infections. 
Besides its antimicrobial properties LL37 plays a central role in innate immune responses 
and inflammation. It has been identified as a potent chemoattractant for mast cells [11], 
monocytes, T lymphocytes and neutrophils [12] through formyl peptide receptor–like 1 
(FPRL-1). The fact that LL37 can attract leukocytes contributes to host defense against 
infections. LL37 also promotes wound healing [9], angiogenesis and arteriogenesis [13] 
and acts as immune adjuvant [14].  
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Acute wounds normally heal in a very orderly and efficient manner characterized by four 
distinct, but overlapping phases: hemostasis, inflammation, proliferation and remodeling. 
All these phases are strictly connected and play a key role for a complete and proper 
restoration of the injured tissue [15]. The inflammatory phase is initiated immediately 
upon injury. Several inflammatory cells migrate to the wound site to fight infection and 
remove debris. The proliferative phase is characterized by the formation of granulation 
tissue, epithelialization, and angiogenesis. Then, the new collagen matrix becomes cross-
linked and organized during the final remodeling phase. Numerous cell-signaling events 
are required to generate this efficient and highly controlled repair process. 
In this work, we demonstrate that P-LL37 produced by recombinant techniques in our 
laboratory [16] preserves its immunophysiological properties and promotes wound 
healing through re-epithelialization and vascularization in dexamethasone-treated mice. 
 
 
4.2  Materials and Methods 
4.2.1 Animals 
C57BL/6 mice experiments were conducted according to accepted standards of humane 
animal care (Declaration of Helsinki, European Community guidelines (86/609/EEC) and 
Portuguese Act (129/92) for the use of experimental animals). 
 
4.2.2 Reagents 
All chemicals, media and reagents were purchased from Sigma-Aldrich except stated 
otherwise. Synthetic LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was 
purchased from Bachem, Switzerland. Recombinant P-LL37 
(PLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) was expressed and purified as 
described previously [16]. Briefly, the DNA encoding the fusion protein LK-CBM3-LL37 
was successfully cloned in pET21a and expressed in E. coli BL21 DE3 (Novagen) in 
Luria-Broth (LB) medium. The fusion protein was purified on cellulose CF11 and formic 
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acid was applied to cleave LL37 from the fusion carrier (LK-CBM3). The resulting 
recombinant P-LL37 was finally purified by reverse-phase HPLC. 
 
4.2.3 Culture of murine bone marrow-derived macrophages (BMDM); 
suppression of TNF production by LPS-activated macrophages 
Macrophages were obtained from mouse bone marrow as follows: mice were sacrificed 
and femurs and tibias removed under aseptic conditions. Bones were flushed with Hanks’ 
balanced salt solution. The resulting cell suspension was centrifuged at 500g and 
resuspended in RPMI 1640 medium supplemented with 10 mM HEPES, 10% heat-
inactivated fetal bovine serum (FBS), 60 µg/ml penicillin/streptavidin, 0.005 mM "-
mercaptoethanol (complete RPMI [cRPMI]), and 10% L929 cell conditioned medium. To 
remove fibroblasts or differentiated macrophages, cells were cultured on cell culture 
dishes (Sarstedt, Canada), overnight at 37°C in a 5% CO2 atmosphere. Then, 
nonadherent cells were collected with warm cRPMI, centrifuged at 500g, distributed in 
96-well plates (Sarstedt, Canada) at a density of 1x105 cells/well, and incubated at 37°C 
in a 5% CO2 atmosphere. Four days after seeding, 10% of L929 cell conditioned medium 
was added, and the medium was renewed on the seventh day. After ten days in culture, 
cells were completely differentiated into macrophages. This method allows for the 
differentiation of a homogenous primary culture of macrophages that retain the 
morphological, physiological and surface markers characteristics of these phagocytic 
cells [17-19]. LPS was then incubated with the macrophages culture. At the same time, 
synthetic LL37 and P-LL37 were added at different concentrations. After 24h, the 
supernatants were removed and tested for TNF-# production by ELISA (eBioscience). 
 
4.2.4 Cell culture experiments  
Human microvascular endothelial cells (HMECs) and human umbilical vein endothelial 
cells (HUVECs) were used in the experiments. HMECs were cultured in RPMI 1640 
medium supplemented with 10% FBS, 1% penicillin/streptomycin, 4.76 g/l of HEPES, 1 
ml/L of epidermal growth factor (EGF) and 1 mg/l of hydrocortisone. HUVECs were 
cultured in medium 199 (M199) supplemented with 0.1 mg/ml of heparin, 20% FBS, 1% 
penicillin/streptomycin and 2 µl/ml endothelial cell growth supplement (ECGS). Rat bone-
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marrow mesenchymal stem cells (MSCs) were cultured in Dulbecco's Modified Eagle 
Medium (DMEM) supplemented with 10% FBS and 1% penicillin/streptomycin. The cells 
lines were maintained at 37ºC in a humidified 5% CO2 atmosphere. 
 
4.2.5 MTS toxicity assay 
HMECs (2'105 cells/ml) were grown until 70-90% confluence and incubated with different 
concentrations of synthetic and recombinant LL37 for 24h in 96-well plates. Toxicity was 
confirmed using 10% DMSO. Cells were washed twice with PBS and their viability was 
assessed using Cell Titer 96®Aqueous ONE Solution Reagent (MTS [3-(4,5- 
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo-phenyl)-2H-tetrazolium] 
colorimetric assay (Promega, Madison, EUA), according to the instructions provided by 
the manufacturer. Optical density was measured at 492 nm. Results are expressed as 
percentage of control, which was considered to be 100%. 
 
4.2.6 BrdU proliferation assay 
HMECs and HUVECs (6'104 cells/ml) were cultured in 24-well plates to adhere 
overnight. The cells were then incubated for 48h with synthetic and recombinant LL37, in 
the presence of 5-bromodeoxyuridine (BrdU) solution at a final concentration of 0.01 mM. 
Proliferation was quantified using In-Situ Detection Kit (BD Biosciences Pharmigen, 
USA), according to manufacturer’s instructions. The results are given as mean ± SEM 
and are expressed as percentage of control, which was considered to be 100%. 
 
4.2.7 Migration analysis 
Migration assays were performed in transwell BD-matrigel basement membrane matrix 
inserts (BD-Biosciences, Belgium). The chemotactic capacity of LL37 was evaluated by 
counting the cells that migrated through the membranes. Transwell inserts containing an 
8 !m pore-size PET membrane coated with a uniform layer of matrigel basement 
membrane were used. HUVECs (5'104cells/ml) were seeded on inserts in serum-free 
medium, and placed on wells containing medium complemented with FBS 2% and 
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recombinant or synthetic LL37 at a concentration of 5 µg/ml. For MSCs (5'104cells/ml), 
the inserts were placed on wells containing DMEM with BSA 0.1% and recombinant LL37 
at a concentration of 5 µg/ml. After incubation for 24 h membranes were removed from 
inserts, stained with DAPI-methanol for 5min and visualized under a fluorescence 
microscope. The invading cells of each membrane were counted and the results are 
expressed as percentage of control, which was considered to be 100%. 
 
4.2.8 Angiogenesis 
The ability of LL37 to promote the formation of capillary-like structures was examined in 
Matrigel assay. HMECs and HUVECs (3'104 cells/well) were incubated with 5 µg/ml of 
recombinant and synthetic LL37 for 24h on matrigel-coated 96-well plates. The capillary-
like structures in each well were then counted and results are expressed as percentage 
of control, which was considered to be 100%. 
 
4.2.9 Wound healing assay 
C57BL/6 mice (purchased at Charles River, Wilmington, MA) with 8-12 weeks old were 
used in this study. After general anesthesia, hair on the dorsal side of the animals was 
shaved and the skin was cleaned with 70% ethanol. A 5 mm skin biopsy punch was used 
to create full thickness cutaneous wounds under aseptic conditions. Two wounds were 
created on the dorsal surface with one on each side of the midline. LL37 (recombinant or 
synthetic) and sterile water were applied topically twice a day (2'10 !g in 50 !l). Wounds 
were left open and not covered by any type of dressing. To impair healing, mice were 
treated daily with dexamethasone (0.25 mg/kg body weight, intramuscularly). Mice were 
examined daily for wound-healing progression. After 7 days, the animals were euthanized 
and wound tissue was collected for histological and immunohistochemistry studies. Skin 
wound tissue specimens were fixed in 10% neutral-buffered formalin solution and 
paraffin-embedded. Histological analyses were performed in 5-!m tissue sections. 
 
Chapter 4|Wound healing activity of LL37 
 107 
4.2.10 Immunohistochemistry  
Microvessel density (MVD) was evaluated in each formalin-fixed paraffin-embedded 
wounded tissue section by immunohistochemistry. Tissue slides were incubated 
overnight with an anti-CD31 antibody. Briefly, six areas with the highest visible blood 
vessel density (marked by the vessel marker) per section were selected, and the number 
of blood vessels was counted per high-power field. 
 
 
4.3  Results  
4.3.1 Recombinant P-LL37 neutralizes the activation of macrophages by LPS 
Murine macrophages are known to induce several cytokines, including tumor necrosis 
factor # (TNF-#), upon LPS activation. LPS was added to macrophage cultures to a 
concentration of 10 ng/ml, either alone or in the presence of 20 !g/ml of recombinant P-
LL37 or synthetic LL37. Cultures were then incubated for 24h. The absence of LPS in the 
recombinant protein was confirmed using the limulus amoebocyte lysate test (data not 
shown). As expected, the recombinant P-LL37, as well as the synthetic peptide, 
neutralized the LPS-mediated activation of macrophages (figure 4.1).  
 
Figure 4.1. Recombinant and synthetic LL37 inhibit the TNF-# production by LPS-activated 
macrophages. *** P ( 0.001 versus control 
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4.3.2 Toxicity 
In order to evaluate the cytotoxicity of recombinant P-LL37, HMECs were cultured for 24h 
in the presence of the peptide and the cell viability was evaluated by MTS. DMSO 10% 
was used as cytotoxic agent, a positive control. As shown in figure 4.2, P-LL37 did not 
affect viability of HMECs at any of the concentrations used. Actually, with 50 and 500 
ng/ml of P-LL37, a slight increase of viability was observed, indicating that the 
recombinant peptide P-LL37 might have promoted proliferation, as previously shown by 
Koczulla et al. [13].  
 
Figure 4.2. Cytotoxicity of P-LL37 in confluent HMECs using MTS assay. Three independent 
experiments were performed in duplicate. *** P ( 0.001 versus control 
 
4.3.3 P-LL37 promotes proliferation, migration and tubule-like structures 
formation by endothelial cells 
 
Proliferation of HMECs and HUVECs was evaluated using the BrdU incorporation assay. 
Synthetic LL37 (5 !g/ml) was used as a positive control and 100 !M of deoxycholic acid 
(DCA), an antagonist of FPRL-1, as negative control. DCA attenuates the activation of 
FPRL-1, by binding to the cell membrane and interfering with the access of the receptor 
to its agonists [20]. Figure 4.3 demonstrates that P-LL37 promoted proliferation with 
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concentrations as low as 50 ng/ml in HMECs (a) and the effect at 5 !g/ml was very 
similar to the one obtained using the synthetic LL37. The proliferation of HUVECs (b) was 
inferior but once again there were no significant differences between synthetic and 
recombinant peptides. 
 
Figure 4.3. Effects of synthetic and recombinant LL37 in HMECs (a) and HUVECs (b) proliferation 
assessed by BrdU assay. P-LL37 and synthetic LL37 promoted similar proliferation of endothelial cells. 
Three independent experiments were performed in duplicate. * P ( 0.05 and ** P ( 0.01 versus control. 
 
 
Next, the chemotactic and angiogenic activities of P-LL37 were evaluated. Figure 4.4 
illustrates the invasion assays performed with HUVECs (a) and MSCs (b). Again, P-LL37 
was able to increase cell invasiveness capacity both in HUVECs and in MSCs. The 
capacity of LL37 to promote the formation of capillary structures was assessed with 
HUVECs and HMECs using matrigel as three-dimensional scaffold (Figure 4.5). The use 
of LL37 had a strong effect in angiogenesis. In fact, it almost doubled the number of 
capillaries formed by HUVECs and HMECs. 
 
a b 
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Figure 4.4. Invading cells relative to the initial amount of HUVECs (a) and MSCs (b) cultured using a 
double-chamber assay. Results are means ±SEM of 3 independent experiments performed in duplicate 
and expressed relatively to control. * P ( 0.05 and ** P ( 0.01 versus control. 
 
 
Figure 4.5. Recombinant and synthetic LL37 promote angiogenesis in vitro. Left: Capillary-like 
structures formation of HMECs, after treatment with 5 !g/ml of LL37, visualized under a phase-contrast 
microscope. Figures are representative of the whole cultures. Right: Quantification of capillary-like 
structures assembly. Results are means ±SEM of 3 independent experiments performed in triplicate 
and expressed relatively to control. * P ( 0.05 and ** P ( 0.01 versus control. 
a b 
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4.3.4 Wound healing assays 
To further examine the effects and biological activities of synthetic and recombinant LL37, 
wound healing experiments in dexamethasone-treated mice were performed. The 
peptides or vehicle were topically applied daily for seven days in the 5 mm skin wounds. 
Dexamethasone was used to impair healing. Figure 4.6 illustrates the wounds after daily 
treatment with recombinant LL37 (two applications of 10 !g each) or vehicle, on day 
seven. The effect of the peptide on wound closure is very strong when comparing to 
control.  
 
 
Figure 4.6. Macroscopic examination of the wounds at day seven. 
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The wound sections stained with hematoxylin and eosin are shown in figure 4.7. No 
significant differences are found in the granulation tissue with a high number of 
granulocytes in both cases. However, regarding re-epithelialization, the lesions treated 
with control or synthetic and recombinant LL37 present large differences. In the control, it 
is clear that the keranocytes layer is incomplete. On the contrary, in the wounds treated 
with LL37, the re-epithelialization is almost complete, demonstrating that the healing 
process is accelerated. More, a high number of blood vessels can be identified in the 
wounds treated with LL37 (pointed by the arrows), indicating that synthetic or 
recombinant LL37 strongly promote angiogenesis in vivo. These results were verified by 
immunohistochemistry (figure 4.8). The angiogenic process was confirmed, in our 
experimental model, by the augmented micro vascular density evaluated by the means of 
newly formed vessels counted after immunostaining. The wounds treated with either 
synthetic or recombinant LL37 possess a significantly higher number of new blood 
vessels. Moreover, the vessels in the tissues treated with the peptide are much larger. 
Several experiments were performed with both recombinant and synthetic LL37 and 
similar results were observed. These results clearly demonstrate the ability of LL37 to 
promote wound healing is a very promising result. 
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Figure 4.7. Hematoxylin and eosin stained micrographs of wound tissue sections treated with control, 
synthetic LL37 and recombinant P-LL37. The rectangle identifies an area further investigated in a 
higher magnification picture. At day 7, re-epithelialization is almost complete in the wounds treated with 
LL37 and a high number of blood vessels are present (pointed by arrows). 
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Figure 4.8. Left: representative immunostaining of skin wounds samples treated with vehicle or LL37 at 
day 7. Arrows indicate the blood vessels. Right: Quantification of blood vessels. Results are means ± 
SEM of 3 independent experiments and are expressed as percentage of control. ***P ( 0.001 versus 
control. 
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4.4  Discussion 
A variety of endotoxins released by the outer membrane of Gram-negative bacteria, 
namely the lipopolysaccharide (LPS)-protein complex, play an important role in 
pathogenesis of many exogenous respiratory diseases. The massive release of LPS can 
lead in extreme cases to endotoxic shock and therefore, death [21]. Many antibiotics 
release endotoxin by disrupting the cell wall [22, 23], and patients cured of bacterial 
infections can suffer from endotoxic shock. The activation of macrophages is started 
when LPS binds the LPS-binding protein (LBP). In turn, LBP binds the macrophage 
surface protein CD14, the primary receptor of LPS, and is 100-fold more potent than LPS 
alone [24]. The antimicrobial activity of the peptide LL37 results from the disruption of the 
bacteria cell wall; however, LL37 can also neutralize LPS activity by forming high affinity 
complexes [25, 26].  
The TNF-# production was very low in the presence of either the recombinant or the 
synthetic peptides, indicating that recombinant P-LL37 has affinity for LPS. The 
recombinant peptide only differs from the synthetic in one amino acid, a neutral proline 
resulting from the formic acid hydrolysis [16]. Therefore, the global net charge (+5) 
remains unaltered. Since electrostatic and hydrophobic interactions are the predominant 
forces driving the binding between antimicrobial peptides and LPS, these results were 
expected. However, Rosenfeld et al. [24] described that a strong binding of AMPs-LPS 
might not be sufficient to neutralize LPS-induced macrophage activation. In fact, those 
authors showed that the AMP magainin, although binding LPS with high affinity, did not 
reduce the production of TNF-#. Some AMPs, including LL37, can compete with LPS on 
its binding site within the CD14 receptor, modulating the TLR signaling pathway involving 
NFkB [27]. Therefore, the inhibition of TNF-# production by LL37 is not only caused by 
the interaction with LPS. Overall, these results demonstrate that the recombinant peptide 
P-LL37 is biologically active. 
 
The human antimicrobial peptide LL37 was initially recognized for its antimicrobial 
properties. In fact, it has a broad spectrum of antimicrobial activity against bacteria, fungi, 
and viral pathogens, as summarized by Durr et al. [7]. Several studies reported that 
AMPs loose their antimicrobial activity in elevated salt concentrations and under serum 
conditions [28-30]. This inhibition is less pronounced in the case of LL37, probably due to 
its #-helical structure [31]; however, the peptide becomes inactive against certain 
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organisms - susceptible under low salt conditions - in media with 100 mM NaCl [32]. 
Furthermore, LL37 had no killing activity against Staphylococcus aureus or Salmonella 
typhimurium in the presence of tissue-culture medium [33]. Therefore, the relevance of 
antimicrobial activity in vivo is not clear. However, AMPs are imperative in innate 
immunity, since animals lacking gene expression of these peptides were more 
susceptible to infections [10]. Besides its antimicrobial properties, many other activities 
have been reported for the human peptide LL37. As already stated, LL37 is involved in 
many aspects of innate immunity, like chemotaxis, angiogenesis or wound healing. 
Although not completely understood, these activities have been associated to some cells 
receptors like FPRL-1, P2X7 and epidermal growth factor receptor (EGFR) [34-36]. 
Among these, LL37 only binds directly to FPRL-1 [12], inducing cellular signaling and 
Ca2+ flux [13]. So, we have tested the effects of P-LL37 in proliferation, migration and 
angiogenesis of endothelial cells to ascertain whether the recombinant peptide binds the 
receptor FPRL-1. The results confirmed that P-LL37 promotes proliferation, migration and 
tubule-like structures formation by endothelial cells. 
The effect of P-LL37 in the migration of HUVECs and MSCs is significant, with an 
increase of almost 100% invading cells being observed in both cases. In the experiments 
with HUVECs, synthetic LL37 promoted a very strong increase in invading capacity, 
much superior than the one obtained with P-LL37. This result was surprising, since no 
significant differences were found in the proliferation assays. P-LL37 is obtained by 
recombinant techniques and the batch used in this experiment could not be as pure as 
expected, misleading the concentration quantification. A smaller concentration of the 
recombinant peptide might have been used, which would explain this result. In fact, as 
illustrated in figure 4.5, the formation of capillary structures was very similar using both 
peptides. The invasion assay with MSCs was only performed with control and 
recombinant LL37. Coffelt et al. reported that LL37 was able to chemoattract MSCs 
through the activation of FPRL-1 [37]. Considering all the results obtained, we clearly 
demonstrate that the recombinant LL37 produced in our laboratory is fully active in vitro. 
The N-terminus proline, result of the formic acid hydrolysis, does not interfere with the 
binding of LL37-LPS and to the receptor FPRL-1. 
 
Glucocorticoids affect almost every phase of wound healing because of their inhibitory 
effect on gene expression in various cells [38]. Beer et al. [39] showed that 
dexamethasone inhibits recruitment of various inflammatory cells and gene expression of 
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many key wound healing cytokines and growth factors. During the proliferative and 
remodeling phases, dexamethasone can inhibit the synthesis of several dermal 
extracellular matrix (ECM) proteins, and delay re-epithelialization and fibroplasia. The 
healing of a skin wound is a complex process requiring the collaborative efforts of many 
different tissues and cell lineages and involves the formation of new extracellular matrix, 
cell infiltration, and tissue remodeling. Inflammation and angiogenesis are two 
fundamental physiological conditions implicated in this process. In fact, the formation of 
new blood vessels is a prerequisite of tissue repair and wound healing [40]. As already 
stated and confirmed in this work, LL37 promotes angiogenesis. Moreover, LL37 appears 
to have a very important role in wound healing. In fact, Heilborn et al. [9] showed that the 
use of LL37 antibody inhibited re-epithelialization in a concentration-dependent manner in 
an organ cultured full-thickness ex vivo wound model. Moreover, Carretero et al. [41] 
transferred an adenoviral vector containing LL37 via intradermal injection to excisional 
wounds in ob/ob mice, improving re-epithelialization and granulation tissue formation. 
Considering all these results, we decided to study the effects of the topical application of 
LL37 on wounds. Synthetic and recombinant LL37 strongly accelerated the healing 
process with a re-epithelialization almost complete after 7 days. Moreover, a significant 
number of new blood vessels were present in the wounds treated with the peptide.   
 
The importance of LL37 in wound healing has already been presented, but the topical 
application of LL37 on skin lesions with impaired healing has not been studied so far. In 
this work, we demonstrate that LL37 can be used topically to support wound healing. The 
topical application of the peptide allows a better regulation of the process. The applied 
concentrations can be easily controlled and the administration can be stopped at any 
moment. Moreover, delivery systems can be used to obtain a regulated administration. 
The tight regulation of AMPs is very important since elevated amounts may lead to a 
chronic inflammatory process, as it has been demonstrated for psoriasis and rosacea [42, 
43]. In order to better understand the role of LL37 in wound healing, further experiments 
will be performed, namely with diabetic mice. Diabetic mice have impaired healing and it 
is well known that the healing treatments of diabetic ulcers did not deliver satisfactory 
results. In this type of lesions, angiogenesis seems to be the most compromised phase 
with impairment in VEGF synthesis [44]. Regarding the positive results obtained in this 
work, we believe that the treatment of diabetic ulcers with LL37 will improve wound 
healing. 
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Abstract 
LL37 was initially recognized for its antimicrobial properties. Nevertheless, it has been 
found to have additional defensive roles such as regulating the inflammatory response, 
chemo-attracting cells of the adaptive immune system to wound or infection sites, and 
promoting wound closure. An adjuvant effect for LL37 has also been described.  
We have recently developed a new method for the expression and purification of 
recombinant P-LL37 in E. coli. P-LL37 preserves its immunophysiological properties in 
vitro and in vivo. In this chapter, we tested the adjuvant activity of CRAMP and P-LL37 
after simultaneous administration with Candida albicans Sap2. However, both peptides 
showed no adjuvant effect.  
We demonstrated in previous work that LL37 accelerated the wound healing process in 
dexamethasone-treated mice. Therefore, we decided to study the wound healing effects 
of topically added LL37 in diabetic mice (db+/db+). The effects of LL37 on diabetic mice 
were weaker than the obtained in our previous work. However, histological analysis after 
13 days showed that the wounds treated with LL37 were smaller and presented several 
new skin annexa.   
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5.1  Introduction 
 
There are two major groups of antimicrobial peptides in humans: defensins and 
cathelidicins. All cathelicidins share a similar structure characterized by a highly 
conserved N-terminal domain of about 100 amino acid residues. This cathelin-like domain 
is flanked by a signal peptide (approximately 30 residues long) on its N-terminus, and by 
an antimicrobial peptide region on its C-terminus [1]. The only member of the 
cathelicidins family found to date in humans is LL37/hCAP18, an 18 kDa peptide encoded 
by the gene CAMP. The mature antimicrobial peptide has 37 amino acid residues starting 
with two leucines, hence being named LL37 and is derived by extracellular proteolysis of 
proteinase 3 from the C-terminal end of hCAP18 [2]. It is a 4.5 kDa, cationic (+6), 
amphipathic #-helical peptide, with a broad spectrum of antimicrobial activity [3]. The 
down and upregulation of LL37 have been identified in many diseases. A higher 
concentration of the peptide is more common in the presence of infections. In fact, in 
pulmonary infections the levels of LL37 are augmented two or three fold [4]. A low 
expression of LL37 is associated with skin disorders like atopic dermatitis [5] or chronic 
ulcers [6]. Nizet et al. [7] showed that mice with disrupted Cnlp, the gene coding for 
CRAMP (cathelin-related antimicrobial peptide), showed increased susceptibility to skin 
infections. These mice also exhibited insufficient and delayed wound closure. 
LL37 has been identified as a potent chemoattractant for mast cells [8], monocytes, T 
lymphocytes and neutrophils [9] through formyl peptide receptor–like 1 (FPRL-1). LL37 
also promotes wound healing [6], angiogenesis and arteriogenesis [10]. Kurosaka et al. 
reported that CRAMP could act as an immune adjuvant. The simultaneous administration 
of OVA with CRAMP to mice promoted both humoral and cellular antigen-specific 
immune responses [11].  
Secreted aspartic proteases (Saps) have been described as virulence factors implicated 
in the mechanisms of host colonization by Candida albicans indifferent types of 
candidiasis. Saps degrade a number of cellular substrates, including proteins related to 
immunological and structural defenses, such as IgG heavy chains, #2-macroglobulin, C3 
protein, "-lactoglobulin, lactoperoxidase, collagen and fibronectin [12]. Vilanova et al. 
demonstrated that Sap2 can be successfully used as a vaccination target [13]. In this 
work, the adjuvant activity of LL37 was analyzed, namely the humoral reaction in mice to 
LL37-Sap2 mixtures. 
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Wound healing, or wound repair, is an intricate process in which the skin (or another 
organ-tissue) repairs itself after injury. Because the skin serves as a protective barrier 
against the environment, any break sets in motion the wound healing process, 
characterized by four distinct, but overlapping phases: hemostasis, inflammation, 
proliferation and remodeling [14, 15]. As the blood components spill into the site of injury, 
the platelets release clotting factors as well as essential growth factors and cytokines. 
Following hemostasis, several inflammatory cells migrate to the wound site to fight 
infection and remove debris as well as releasing more growth factors. Once the wound 
site is cleaned out, fibroblasts migrate in to begin the proliferative phase and deposit new 
extracellular matrix. The proliferative phase is characterized by the formation of 
granulation tissue, epithelialization, and angiogenesis. The new collagen matrix then 
becomes cross-linked and organized during the final remodeling phase. In order for this 
efficient and highly controlled repair process to take place, there are numerous cell-
signaling events that are required [15].  
Diabetic foot ulcers, a leading cause of amputations, affect 15% of people with diabetes 
mellitus. Diabetes is the prototypical model of impaired wound healing and several factors 
contribute to wound healing deficiencies [16]. Angiogenesis seems to be the most 
compromised phase in diabetes [17]. Therefore, the restoration of the angiogenesis 
process seems fundamental to reduce impaired healing in diabetes.  
The other objective of this work was to study the wound healing effects of topically added 
LL37 in diabetic mice.   
   
 
 
5.2  Materials and Methods 
5.2.1 Animals 
C57BL/6 and diabetic mice (db+/db+) experiments were conducted according to accepted 
standards of humane animal care (Declaration of Helsinki, European Community 
guidelines (86/609/EEC) and Portuguese Act (129/92) for the use of experimental 
animals). 
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5.2.2 Reagents 
Synthetic LL37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) and CRAMP 
(GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ) were purchased from Bachem, 
Switzerland. Recombinant P-LL37 (PLLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPR-
TES) was expressed and purified as described previously [18]. Briefly, the DNA encoding 
the fusion protein LK-CBM3-LL37 was successfully cloned in pET21a and expressed in 
E. coli BL21 DE3 (Novagen) in Luria-Broth (LB) medium. The fusion protein was purified 
on cellulose CF11 and formic acid was applied to cleave LL37 from the fusion carrier (LK-
CBM3). The resulting recombinant P-LL37 was finally purified by reverse-phase HPLC. 
Sap2 was purified from C. albicans as described by Vilanova et al. [13]. C. albicans was 
grown in Winge medium  for 48 h at 37ºC in an orbital incubator. Culture supernatant 
proteins were concentrated by ultrafiltration with a 10 000-MW cut-off membrane in a 
VivaFlow system (Vivascience, Hanover, Germany), dialysed and separated by ion-
exchange chromatrography on a DEAE-cellulose (DE52; Whatman, Maid-stone, Kent, 
UK) column. Fractions enriched in Sap2 were concentrated by vacuum dialysis using a 
14 000-MW cut-off membrane (Sigma, St Louis, MO). Mannoside constituents were 
removed from this fraction by affinity chromatography in a concanavalin A-sepharose 
column (Amersham Pharmacia, Uppsala, Sweden). Sap2 was finally purified by a 
Pepstatin A affinity-chromatography column (Sigma). 
 
5.2.3 Immunizations 
Two assays have been carried out. In the first one, eight-week-old C57BL/6 mice 
(purchased from Charles River, Barcelona, Spain) were injected intradermically (i.d.) 
twice, with a 3-week intervening period, with 100 !l of the following preparations: 5 !g of 
native Sap2 in PBS; 5 !g of Sap2 in a 1:1 PBS/alum suspension (Al(OH)3 gel; Sigma-
Aldrich); 5 !g of Sap2 plus 80 !g (20 nmol) of CRAMP in the first injection and 5 !g of 
Sap2 plus 60 !g (15 nmol) of CRAMP in the second injection.  
In the second experiment, mice were injected intraperitoneally (i.p) twice, with a 3-week 
intervening period, with 100 !l of the following preparations: 5 !g of Sap2 in PBS; 5 !g of 
Sap2 in a 1:1 PBS/alum suspension (Al(OH)3 gel; Sigma-Aldrich); 5 !g of Sap2 plus 150 
!g (38 nmol) of P-LL37 in the first injection and 5 !g of Sap2 plus 100 !g (25 nmol) of P-
LL37 in the second injection.  
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Alum was used as a positive control adjuvant. On days 21 and 42 (21 days after the 
second injection), blood samples were collected from each mouse. Serum was separated 
from each blood sample and used for measurement of the anti-Sap2 immunoglobulin.  
 
5.2.4 Antibody detection 
The quantitation of total Sap2-specific Immnunoglobulin G (IgG) in mouse serum was 
performed by enzyme-linked immunosorbent assay (ELISA) as previously described by 
Vilanova et al. [13]. Briefly, polystyrene microtitre plates (Nunc, Roskilde, Denmark) were 
coated with 5 !g/ml of Sap2 and incubated at 37ºC for 1 hour. Wells were then saturated 
for 1 hour at room temperature with 1% BSA in Tris-saline Tween 20 (TST) buffer, pH 
8.0. Serial dilutions of the serum samples were then plated and incubated for 2 hours at 
room temperature. After washing, alkaline phosphatase-coupled monoclonal goat anti-
mouse IgG (Southern Biotechnology Associates, Birmingham, AL) was added and 
incubation continued for 30 min at room temperature. After washing, the bound 
antibodies were detected by development with substrate solution containing p-nitrophenyl 
phosphate (Sigma) and the reaction was stopped by the addition of 0.1 M EDTA, pH 8.0. 
The absorbance was measured at 405 nm. The levels of anti-Sap2 IgG are illustrated as 
the reciprocal logarithmic value of the highest dilution that gave an absorbance )0.1 
above the control value. 
5.2.5 Wound healing assays 
Diabetic female mice (db+/db+) (purchased at Charles River, Barcelona, Spain) with 8-10 
weeks old were used in this study. After general anesthesia, hair on the dorsal side of the 
animals was shaved and the skin was cleaned with 70% ethanol. A 5 mm skin biopsy 
punch was used to create full thickness cutaneous wounds under aseptic conditions. Two 
wounds were created on the dorsal surface, one on each side of the midline. Synthetic 
LL37 and sterile water were applied topically twice a day (2'10 µg in 10 µl). Wounds 
were left open and not covered by any type of dressing. Mice were examined daily for 
wound-healing progression. After 6 and 13 days, the animals were euthanized and 
wound tissue was collected for histological studies. Skin wound tissue specimens were 
fixed in 10% neutral-buffered formalin solution and paraffin-embedded. Histological 
analyses were performed in 5-µm tissue sections. The 5 µm-thick sections were mounted 
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on glass slides, dewaxed, rehydrated with distilled water, and stained with hematoxylin 
and eosin according to routine procedures for light microscopy. As part of the histological 
evaluation, all slides were examined by a pathologist without knowledge of the previous 
treatment. 
 
 
5.3  Results and discussion 
5.3.1 Adjuvant activity of CRAMP and P-LL37 
Kurosoka et al. reported a novel activity for CRAMP, the cathelin-related AMP in mice. 
This is the only work that describes the adjuvant activity of this AMP. Compared with 
immunization with ovalbumin (OVA) alone, the immunization with OVA plus CRAMP 
markedly increased the production of OVA-specific serum IgG antibody (Ab). CRAMP 
enhanced the anti-OVA IgG Ab response in a dose-dependent manner, with higher titers 
of serum anti-OVA IgG Ab induced by 40 than 10 nmol of CRAMP [11]. The authors also 
reported that CRAMP augmented both Th1- and Th2-type antigen-specific immune 
responses (helper T cell responses). In fact, there was no obvious selective 
enhancement of either IgG1 or IgG2a and the splenocytes from mice immunized with 
OVA plus CRAMP at 40 nmol produced both Interleukin-4 (IL-4) and interferon-gamma 
(IFN-%) in response to OVA stimulation. The production of the IgG2a subclass of Ab and 
IFN-% is associated with Th1-type cytokine production while IgG1 Abs and IL-4 are 
associated with Th2-type cells. These responses should be fully functioning but none 
should be dominant. In fact, in the case of autoimmune diseases and severe allergies, 
one response has gained control of the system.  
To better understand and characterize the adjuvant activity of CRAMP and LL37, 
immunizations studies were performed on mice using the C. albicans Sap2 as antigen. 
Vilanova et al. showed that Sap2 incorporated in alum adjuvant provided efficient immune 
protection against candidiasis [13]. The anti-Sap2 IgG concentrations were significantly 
higher in mice immunized with Sap2 than in the controls.  
In this work, we first tested the adjuvant activity of CRAMP after i.d. injection. Then, we 
tested the adjuvant effect of i.p. injected P-LL37. CRAMP is similar to LL37 in structure, 
tissue distribution and antimicrobial activity. In fact, both peptides have been used in mice 
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models with similar results Alum was used as positive control. The results are illustrated 
in figure 5.1. 
 
Figure 5.1. Serum IgG enzyme-linked immunosorbent assay (ELISA) titres of anti-Sap2 IgG in sera 
collected 21 days after the first immunization or when the mice were killed, 21 days after the second 
immunization (day 42). a: first experiment with CRAMP (i.d injections); b: second experiment with P-
LL37 (i.p injections). 
 
Figure 5.1 shows that CRAMP and P-LL37 had no adjuvant activity. The AMPs did not 
enhance the anti-sap2 IgG Abs when comparing with Sap2 alone or with Sap2 plus the 
positive control Alum. The use of different administrations routes (i.d. and i.p. injections) 
as well as different peptide concentrations, did not deliver better results. In the first 
experiment 80 !g (20 nmol) of CRAMP were injected intradermally in the first day and 60 
!g (15 nmol) after 21 days. A very slight increase of anti-sap2 IgG Abs was seen after 21 
days, however these were quite below the quantities obtained with Alum. A new 
experiment was performed, using higher concentrations of P-LL37: 150 !g (38 nmol) 
were injected intraperitoneally in day one and 100 !g (25 nmol) were injected on day 21. 
Once again, no adjuvant activity was detected.  
LL37 and CRAMP can chemoattract mast cells [8], monocytes, T lymphocytes and 
neutrophils [9]. Moreover, LL37 is a potent modifier of dendritic cells differentiation [19]. 
Kurosaka et al. suggested in their work that these properties contribute to the 
enhancement of antigen-specific immune responses [11]. OVA and Sap2 are both 
negatively charged at physiological pH (pI=4.7 and pI=4.25 respectively); so, the 
electrostatic interactions of CRAMP and LL37 with OVA or Sap2 should be very similar. 
Therefore, the in vivo biological activities like chemotaxis or DCs differentiation that may 
contribute to the adjuvant activity should also be similar. Further experiments using OVA 
a b 
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and other antigens should be performed to clarify the actual adjuvant activity of LL37 and 
to better understand the associated mechanisms of action. 
 
 
5.3.2 Wound healing experiments on diabetic mice 
We reported in chapter 4 that the topical application of LL37 accelerated the wound 
healing process in dexamethasone-treated mice. The experiments showed that LL37 
greatly increased the vascularization of the wounds. As already stated, diabetes is the 
prototypical model of impaired wound healing and angiogenesis seems to be the most 
compromised phase [17]. In fact, therapeutic interventions aiming at restoring the 
impaired VEFG production have succeeded in ameliorating the wound healing process in 
experimental model of diabetic mouse [20-23]. Considering these reports and our 
previous positive results we tested the effect of topically added LL37 in diabetic mice 
(db+/db+). Two applications of 10 !g in 10 !l each were applied daily. Two wounds were 
created on the dorsal surface of the animals. LL37 was applied on the left wound and 
sterile water on the right one. After 6 days the first group of 4 mice was euthanized. The 
treatment was continued for the second group until day 13 and the last 4 mice were then 
euthanized. Figure 5.2 illustrates the wounds after 6 and 13 days. After 6 days the 
wounds were still wide open but after 13 days the healing process was almost complete 
(the wounds were barely visible and are pointed with arrows). The macroscopic 
examination of the wounds shows no significant differences between the treatment with 
LL37 and sterile water. 
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Figure 5.2. Macroscopic examination of the wounds at day 6 and day 13. LL37 was applied on the left 
wounds and sterile water on the right. After 13 days the wounds are almost healed (pointed by white 
arrows). 
 
We decided to apply both solutions on each animal to avoid misleading conclusions and 
to better compare and control the evolution of the wounds. Indeed, some animals 
regenerate wounds faster than others. For example, the fourth mouse euthanized after 6 
days was healing faster than the other three (figure 5.2). If this animal were only treated 
with LL37, the conclusion would have been incorrect. 
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The wound tissue was collected for histological studies. The wound sections stained with 
hematoxylin and eosin are shown in figure 5.3. After 6 days, no significant differences 
can be identified comparing the treated and control wounds. Both wounds in each animal 
present very large scabs and the healing process is still at the beginning. In fact, the 
keratinocytes layer is still very incomplete. The large scabs difficulted the processing of 
the skin wound sections. At the end of the process, the 5-!m tissue sections were very 
damaged.  
After 13 days the healing process is almost terminated. The epidermis is complete and a 
small number of granulocytes are still present, indicating that the inflammatory phase is 
finished. However, there are now visible differences between the wounds treated with 
LL37 and the ones treated with control. The control wounds are still much larger than the 
ones treated with LL37. The micrographs shown (figure 5.3) were taken from the same 
animal with a 4X magnification. The picture that shows the control wound treated after 13 
days is a merge of two photographs. This way, the entire wound is displayed. 
Comparatively, the wound treated with LL37 is much smaller. The limits of the wounds 
are pointed with black arrows. Moreover, the wounds treated with LL37 present what 
appears to be new skin annexa. These annexa, pointed with white arrows, could originate 
new hair follicles. Similar results were consistently obtained in the 4 animals. We cannot 
conclude whether these annexa will really generate new hair. Experiments should be 
performed over a longer time frame (e.g. 20 days or a month) to ascertain whether this 
hypothesis proves to be correct.  
The healing process of dexamethasone-treated mice (chapter 4) was faster with an 
almost complete re-epithelialization after 7 days. The hematoxylin and eosin stained 
micrographs taken at day 6 using the diabetic mice were rather damaged, not enabling a 
proper comparison of the wounds vascularization and the effect of LL37. Differences can 
be seen after 13 days but LL37 did not accelerate the healing process very significantly, 
as judged from the macroscopic/external inspection. 
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Figure 5.3. Hematoxylin and eosin stained micrographs of wound tissue sections treated with control, 
or synthetic LL37 after 6 and 13 days. After 13 days, the wound treated with LL37 is much smaller and 
presents several skin annexa (pointed with white arrows). The limits of the wounds are pointed with 
black arrows. The wound treated with control after 13 days is a merge of two micrographs. 
Chapter 5|Adjuvant and Wound healing activities of LL37  
 134 
5.4  Conclusions 
The application of LL37 in the wounds of diabetic mice did not deliver an effect as strong 
as the one obtained on dexamethasone-treated mice. However, the histological analysis 
of wound sections after 13 days revealed encouraging results. In fact, the wounds treated 
with LL37 were smaller and presented many more skin annexa.  
Wound healing is a complex process that involves many different cells and growth 
factors. To better understand the effect of LL37, further experiments need to be 
performed and a better characterization of the process is required. The expression and 
quantification of angiogenic factors associated to wound healing, such as VEGF, bFGF 
and angiopoietins, as well as the effect of LL37 on the expression of proteins in the 
wounds must be evaluated. Also, it is important to assess whether LL37 induces systemic 
angiogenic and inflammatory responses. 
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Two antimicrobial peptides, magainin-2 and LL37, were fused to the family 3 CBM from 
C. thermocellum for recombinant expression in E. coli, aiming the affordable production 
and purification using cellulose as affinity matrix. Both AMPs were cloned at either the N- 
or C-terminus of the CBM3. The N-terminal AMP MAG2-D was sucessfully expressed, 
cleaved and purified from the fusion partner LK-CBM3 but showed no antibacterial 
activity against E. coli K12. The expression of C-terminal MAG2 from the construction LK-
CBM3-MAG2 was not successful. The peptide may have suffered proteolysis during the 
recombinant expression. The human AMP LL37 was sucessfully cloned, cleaved and 
purified from the N- or C-terminus of the fusion partner LK-CBM3. However, only the 
recombinant P-LL37 obtained from the C-terminally fused protein (LK-CBM3-LL37) 
showed antibacterial activity against E. coli K12, with a MIC of 180 !g/ml. Regarding 
these results we can conclude that the negatively charged aspartic acid, resulting from 
the formic acid cleavage, is the cause for the non-activity of MAG2-D and M-LL37-D.  
The expression of AMPs in E. coli is challenging because they are toxic to the host and 
sensitive to proteolytic degradation. In this work, different results were obtained. MAG2 
was overexpressed in E. coli BL21 but suffered proteolysis in E. coli M15. LL37 was 
successfully expressed in E. coli BL21 but only in the insoluble form. The insoluble 
expression of LL37 can protect the host from the toxicity of the AMP but would also 
protect LL37 from proteolysis.  
Overall, the methodology used in this work for the recombinant expression of AMPs 
compares advantageously to other protocols previously described, having fewer 
purification steps and using cellulose for purification. In fact, it allowed the successful 
expression and purification of MAG2-D, M-LL37-D and P-LL37. In future work, the 
expression of MAG2 at the C-terminus of LK-CBM3 will be attempted in different E. coli 
strains to avoid proteolysis and to finally achieve the production of the AMP with 
antimicrobial activity. 
 
The cathelicidin derived human peptide LL37 has a broad spectrum of antimicrobial and 
immunomodulatory activities. The recombinant peptide P-LL37 with a N-terminus proline, 
produced using our new method, preserves its immunophysiological properties in vitro 
and in vivo. P-LL37 neutralized the activation of macrophages by lipopolysaccharide 
(LPS). Besides, the peptide induced proliferation, migration and tubule-like structures 
formation by endothelial cells.  
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The adjuvant activity of LL37 was also assessed using Sap2 as antigen. However, nor 
LL37 nor synthetic CRAMP showed adjuvant activity. The AMPs did not enhance the 
anti-sap2 IgG Abs when comparing with Sap2 alone or with Sap2 plus the positive control 
Alum. In future work, similar experiments will be performed using OVA and other peptides 
as antigen, to conclude whether LL37 has indeed adjuvant activity or whether this is 
specific to some antigens. 
The results obtained in this work using LL37 in wound healing experiments may have 
therapeutic relevance. We showed that the topical application of recombinant or synthetic 
LL37 in dexamethasone-impaired wound healing mice increased vascularization and re-
epithelialization, accelerating the wound healing process. This is the first work that 
describes the successful improvement of wound healing through the topical 
administration of LL37. These experiments simulate what might be a therapeutic 
application under a clinical setting. Similar experiments were performed in impaired 
healing diabetic mice. The topical application of LL37 on diabetic mice wounds did not 
accelerate the healing process very significantly. However, histological analysis after 13 
days showed encouraging results. In fact, they revealed that the wounds treated with 
LL37 were smaller and presented several new skin annexa that could originate new hair. 
Further experiments need to be performed and a better characterization of the process is 
required. A more comprehensive characterization of the the role played by LL37, using 
different models of tissue regeneration, is thus required to estimate the potential of this 
peptide for for therapeutic applications. The expression and quantification of angiogenic 
factors associated to wound healing, as well as the effect of LL37 on the expression of 
proteins in the wounds must be evaluated. Also, it will be important to assess whether 
LL37 induces systemic angiogenic and inflammatory responses.  
 
The major results of this thesis are: 
• We developed a new, fast and cost-effective method for the production of AMPs 
using the CBM3 as fusion partner; 
• The recombinant peptide P-LL37 maintains all its biological activity in vitro and in 
vivo. We demonstrated that LL37 strongly accelerated wound healing in 
dexamethasone-treated mice. Encouraging results were obtained with diabetic 
mice. 
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Suggestions for future work include the following main topics: 
• To test different constructions to achieve the expression of recombinant magainin-
2; 
• To further improve the productivity of LL37 using the E. coli expression system 
and the CBM3 as a fusion partner; 
• To comprehensively estimate the therapeutic potential of LL37 by testing the 
effect of the application of the peptide in different systems of wound and tissue 
regeneration; 
• To develop a delivery system for the topic controlled release of LL37 for wound 
regeneration. 
  
 
 
 
